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Abstract 
-synuclein is the third and last discovered member of the synuclein family, it is 
expressed mostly in the nervous system and its physiological function is still 
unknown. -synuclein has been claimed to play a role in mammary gland 
tumourigenesis as its overexpression in cancer cells was shown to inhibit apoptosis 
and stimulate growth, proliferation, survival, motility and metastasis. However, the 
role of endogenous -synuclein in mammary gland tumourigenesis has not been 
studied in an appropriate in vivo model. The results obtained in this study show that 
-synuclein is not required for the normal development of the mammary gland at any 
developmental stage - embryonic, pubertal or reproductive. Furthermore, ablation of 
-synuclein did not prevent induction of mammary gland tumours by activated ErbB2 
transgene in mammary gland epithelium. Unexpectedly, transgenic activated ErbB2 
hemizygous, -synuclein knockout female mice developed slightly more tumours with 
a significantly shorter tumour latency than the wild type littermates. These animals 
also exhibited similar tumour growth rates and metastases to the lungs, and a 
slightly shorter survival. Overall, a trend for accelerated tumourigenesis in the 
absence of -synuclein was observed. Thus, it is feasible that the aberrant 
expression of -synuclein reported in advance-stage tumours and metastases 
reflects activation of pathways aimed at repressing rather than enhancing 
tumourigenesis, as widely thought. Future studies will clarify the role of -synuclein in 
ErbB2-induced mammary gland tumourigenesis. 
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1.1. Breast cancer facts 
Breast cancer is the most common type of cancer in women worldwide. 
Approximately 1.38 million women were diagnosed in the year 2008, accounting for 
nearly 23% of all diagnosed cancers. In the UK alone, 48788 cases were diagnosed 
in the year 2009 (48417 in women and 371 in men), accounting for nearly 16% of all 
cancers. In the year 2010, breast cancer killed 11556 women and 77 men 
(CancerResearchUK, 2012). Combating the disease includes different types of 
treatments. Some treatments are general in the sense that they are directed against 
any tumour for the purpose of either surgically removing or killing the mass of 
uncontrollably dividing cancerous cells. These include surgical intervention, 
chemotherapy, radiotherapy or, as often the case is, a combination of these. Other 
treatments are directed against certain types of breast tumours. Hormonal therapy is 
aimed at tumours that are hormone positive, namely estrogen receptor (ER) and 
progesterone receptor (PR) expressing tumours, e.g, tamoxifen and aromataze 
inhibitors. Immunotherapy is directed against tumours that express certain 
molecules, such as the monoclonal antibody Trastuzumab that targets ErbB2 
positive tumours and Bevacizumab that targets VEGF positive tumours (Widakowich 
et al., 2007). 
Despite the moderate success achieved in the overall survival rates, most patients 
undergo recurrence largely due to resistance that tumours eventually develop to 
drugs. Moreover, these drugs give rise to side effects that may complicate the 
treatment and limit the advantages to certain people than others. Needless to say, 
success in improving the effectiveness of the existing treatments, developing better 
ones and hopefully curing cancer would ultimately come from increased knowledge 
of the disease, especially at the cellular and molecular levels. Intensive research in 
21 
 
basic and cancer biology has identified many key molecules involved in the 
development of cancer, some of which led to the development of new targeted 
therapies as exemplified above. One possible target claimed by some researchers to 
play a role in breast cancer is a small cytosolic protein called gamma-synuclein (-
synuclein) that belongs to the synuclein family. Before reviewing available literature 
on the possible role of -synuclein in mammary gland tumourigenesis, and to provide 
better context for this thesis, an overview to both the mammary gland and the 
synuclein family will be presented first. 
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1.2. An overview of mammary gland structure and development 
The mammary gland is thought to have evolved from an ancient apocrine gland for 
the ultimate function of nourishing the newborn mammal through the production and 
secretion of milk (Oftedal, 2002). The lactating mammary gland also contributes 
immune factors in milk it produces in order to help protect the young against 
infection. In addition, breast feeding provides a close physical contact between the 
young and the mother which provides developmental benefits (Peaker, 2002). 
Structurally, the mammary gland is a complex secretory organ that is composed of a 
network of branching ducts of epithelial cells residing in a structurally and functionally 
supporting stroma. The ducts consist of two types of epithelial cells: basal, 
contractile myoepithelial cells and luminal cells. The myoepithelial cells form a 
contractile outer layer that helps expel the milk secreted by the underneath luminal 
cells. This cell layer also produces the basement membrane which forms a boundary 
with the surrounding complex stroma. The luminal cells form the inner cell layer in 
the ducts and alveoli that produce and secrete the nourishing milk during lactation 
(Watson and Khaled, 2008). 
The stroma does not just act as a scaffold that supports the branching ducts for 
proper functioning. It houses a heterogenous group of cells including adipocytes that 
form most of the fat pad, mesenchymal cells, fibroblasts, endothelial cells forming 
the blood vessels and many types of immune cells (Watson and Khaled, 2008). 
These stromal components hold bidirectional interactions with the ductal epithelial 
cells to orchestrate the complex developmental processes that drive mammary gland 
development. Figure 1.1 below shows the morphology of a bifurcating terminal end 
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bud (TEB) and a trailing duct with a forming side-branch. The role of TEBs in the 
elongation and proliferation of ducts will be discussed later. 
                            
Figure 1.1. Murine TEB and duct morphology. A: carmine alum whole mount of a 
bifurcating TEB forming two new primary ducts. Two new secondary side-branches 
(open arrowhead) and a possible lateral bud (closed arrowhead) are also shown. 
Scale bar: 200 µm. B: H&E-stained section of a bifurcating TEB showing a side-
branch in the trailing duct (closed arrowhead). Scale bar: 100 µm. C: schematic 
diagram of a bifurcating TEB and trailing duct. The single layer-cap cells and 
multilayer-body cells are highly proliferative and give rise to the myoepithelial cells 
and luminal cells of branching ducts. The collagen-, fibroblast- and immune cell-rich 
collar structure at the neck of the TEB serves stromal-epithelial interactions for 
bifurcation and elongation. A forming side-branch is indicated (closed arrowhead), as 
is the basal lamina and the stromal adipocytes. Adopted from (Sternlicht et al., 
2006). 
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The mammary gland develops through a detailed and complex developmental 
program involving interactions between different types of cells, both epithelial and 
stromal. These intricate interactions are governed by many signalling pathways 
involving hormones and growth factors that are temporally and spatially co-ordinately 
regulated. When such factors and molecular mechanisms are perturbed, either 
because of genetic abnormalities or environmental influences, aberrant proliferation 
and consequently breast cancer may develop. The mammary gland, both in humans 
and rodents, develops through three basic stages: embryonic, pubertal and adult 
(reproductive). A brief overview of these three developmental stages in the mouse 
will be presented, with those in humans and other mammals sharing similar 
processes. 
1.2.1. Embryonic development of the mammary gland 
Fetal mammary gland development is first notable by embryonic day 10.5 (E10.5) 
with the appearance of two ectodermal, multi-cell-layered ridges. These run 
anteroposteriorly on the ventral side between the fore and hind limbs and are 
commonly referred to as the “milk (mammary) lines” (Hens and Wysolmerski, 2005). 
By E11.5, five pairs of disk-shaped “placodes” form along the milk lines at certain 
reproducible locations. These placodes give rise to bulbs of epithelial cells which, by 
E13.5, will have invaginated into the underlying subdermal mesenchyme and 
become the “mammary buds”. The mesenchymal cells surrounding the buds are 
induced to condense and differentiate into a few-cell-layered “mammary 
mesenchyme” arranged radially around the buds. By E15.5, the epithelial cells 
proliferate and further penetrate into the subdermal fat pad precursors and become 
the “mammary sprouts”, concurrently forming a lumen with an opening to the skin 
marked by the “nipple sheath”. At E18.5, end of embryogenesis, the mammary 
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sprout sinks deeper still and forms a main duct that, through the process of 
branching morphogenesis, branches into about 10 to 15 secondary branches, 
forming the “rudimentary mammary gland (anlage)”. At this point, development 
essentially ceases until the onset of puberty (Watson and Khaled, 2008; Hens and 
Wysolmerski, 2005). 
As already stated, embryonic development of the mammary gland involves complex 
interactions between the ectoderm and the underlying mesenchyme, governed by 
many signalling pathways and molecules that are temporally and spatially co-
ordinately regulated. These molecular mechanisms include wingless/integrin (Wnt), 
hedgehog (Hh), epidermal growth factor receptor (EGFR), fibroblast growth factor 
(FGF), GATA DNA sequence-binding proteins (GATA3) and parathyroid hormone-
related protein (PTHrP) signalling. These signalling pathways involve many 
transcription factors and effector molecules including bone morphogenetic protein 4 
(BMP4) and its receptor BMP receptor1A (BMPR1A), homeobox protein MSX-2, T-
box 3, zinc finger protein Gli3, lymphoid enhancer-binding factor 1 (Lef1), FGF10 
and its receptor FGF receptor 2b (FGFR2b), neuregulin3 (Nrg3) and EGFR4 
(ErbB4), among others. Abnormal mammary gland development occurs if these 
factors and signalling pathways are perturbed. Such perturbations may include 
mutations, up/down-regulations and spatial and temporal alterations in the 
expression or availability of key molecules. Abnormalities in the mammary gland 
include misplaced placodes, absence of some or all placodes, mammary hypoplasia 
and nipple loss, supernumerary glands and absence of ductal branching (reviewed in 
(Hens and Wysolmerski, 2005; Watson and Khaled, 2008)). 
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1.2.2. Pubertal development of the mammary gland 
Mammary gland development continues postnatally but in a commensurate manner 
with body growth. With this allometric growth, terminal end buds (TEB) form at the 
end of the growing epithelial ducts that invade the fat pad (figure 1.2-A) (Watson and 
Khaled, 2008). Figure 1.2 below shows a schematic diagram of ductal and 
lobuloalveolar development of the murine mammary gland at different pubertal and 
reproductive stages. 
 
 
 
Figure 1.2. Schematic diagram of murine adult mammary gland development. A (pre-
pubertal development): allometric growth of epithelial ducts led by migrating terminal 
end buds (TEB) (LN: lymph node). B (pubertal development): ductal morphogenesis 
extends throughout the fat pad to create an “open” architecture. C-E (early gestation- 
lactation): robust lobuloalveolar development produces secondary and tertiary 
branches, and alveoli differentiate to fill the entire fat pad. F (Involution): post-
lactational regression of surplus epithelia returns the mammary gland to a pre-
pregnant state. Adopted from (Watson and Khaled, 2008). 
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Robust branching morphogenesis begins with the rising levels of serum estrogens at 
puberty which induce the formation of TEBs at the distal ends of ducts (figure 1.2-B). 
TEBs, made up of an outer layer of progenitor cap cells and an inner multicellular 
layer of body cells, are the sites of active cellular proliferation and differentiation 
during ductal morphogenesis. They respond to estrogens and proliferate to elongate 
the ducts and undergo a bifurcation process to form new primary branches (Hinck 
and Silberstein, 2005). Secondary side-branches sprout laterally from the trailing 
ducts. It is believed that apoptosis occurs in the body cells to create the luminal 
space. Ductal branching continues until an age of about 8-10 weeks, when the 
margins of the fat pad are reached and the TEBs disappear. With each oestrus cycle 
in the mature virgin mammary gland, side-branching and apoptosis occur (Sternlicht, 
2006). In mice devoid of white adipose tissue (WAT), ductal morphogenesis is 
severely limited (only 3-4 short ducts appear at E18) and TEBs are absent, 
highlighting a crucial role of adipocytes in this developmental process (Couldrey et 
al., 2002). It is important that pubertal development creates an “open” architecture of 
ductal trees, open in the sense of leaving most of the fatty pad epithelium-free for the 
massive branching and development of milk-secreting alveoli during gestation and 
lactation (Sternlicht et al., 2006). 
This complex process of branching morphogenesis is regulated by a multitude of 
factors which are expressed by both the epithelium and stromal components to 
provide global and positional cues. These include growth factors and hormones, 
such as estrogen (E) and its receptors (ER-α and ER-β), progesterone (Pg) and its 
receptor (PgR), prolactin (Prl) and its receptor (PrlR), epidermal growth factor (EGF), 
hepatocyte growth factor (HGF), epimorphin/syntaxin2 and transforming growth 
factor β1 (TGF-β1), as well as extracellular matrix molecules and metalloproteinases 
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(MMPs), adipocytes and immune cells (reviewed in (Sternlicht et al., 2006; Watson 
and Khaled, 2008)). Disturbances to these factors and associated signalling 
pathways, whether of genetic or environmental origins, lead to defects in the 
developing mammary gland and may result eventually in tumourigenesis. 
ER-α-null mice did not differ from Wt mice up to puberty, at which time their ducts 
showed no TEBs and failed to invade the fatty stroma (Mallepell et al., 2006). Mice 
with conditional KO of ER-α in the mammary epithelium at different developmental 
stages have revealed that ER-α signalling is required for both proper ductal 
branching during puberty and normal lobuloalveolar development during late 
gestation and lactation (Feng et al., 2007). Furthermore, tissue geometry and 
morphogenetic gradients of locally secreted inhibitors in the microenvironment of the 
mammary epithelium were shown to be critical for the process of branching 
morphogenesis (Nelson et al., 2006). TGF-β1 inhibited tubule elongation at tips and 
side-branching in nearby tubules, suggesting a role in creating the “open” ductal 
architecture important for optimal alveologenesis. This in vitro study suggested that 
the geometry of the elongating duct and its location relative to neighbouring ducts 
may determine the position of branching. The same group also revealed that signal 
intensity and duration have a profound effect on ductal branching. They showed that 
TGFα is sufficient for induction of ductal branching and that the duration of an active 
extracellular signal–regulated kinase 1/2 (ERK1/2) signal is important (Fata et al., 
2007). 
Lumen formation is also crucial to mammary gland development and function, and is 
thought to occur through apoptosis. The pro-apoptotic protein Bcl2-like protein 11 
(Bcl-2L11/Bim) was found to be essential for lumen formation in the TEB during 
puberty (Mailleux et al., 2007). The axonal guidance proteins roundabout homolog 
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protein 1 (ROBO1), slit homolog 2 protein (SLIT2) and netrin1 were also reported to 
affect lumen formation in the TEBs. Mice null for these proteins exhibited 
disorganized, occluded TEBs and ducts, and had spaces between the cap and body 
cells resulting in separated layers, as opposed to normal bi-layered epithelium 
(Strickland et al., 2006). These results point to a role of these axonal guidance 
proteins in maintaining the integrity of the epithelium bi-layer. Moreover, enlarged 
ducts with reduced secondary branching were observed in virgin mice lacking the 
transcription factor CCAAT/enhancer binding protein-β (C/EBP-β) (Seagroves et al., 
1998). These mutant mammary glands also displayed limited ductal side-branching 
and lobuloalveolar development when stimulated with E and Pg. 
1.2.3. Reproductive development of the mammary gland 
1.2.3.1. Gestation, lobuloalveolar development and lactation 
To prepare for nourishment of the newborn during lactation, a gestating mammary 
gland undergoes massive tissue remodelling involving extensive proliferation of the 
epithelial ducts and differentiation of alveoli, the specialized luminal cells that 
synthesize and secrete milk. Concomitant with the massive proliferation of epithelia 
and to make room for such development, remodelling features the dedifferentiation 
of adipocytes whereby they lose their lipid droplets and become long projections 
scattered among the lobuloalveoli. Remodelling also includes expansion of the blood 
vasculature to meet the demands for ample nutrients, such as amino acids, sugars 
and other solutes needed for milk synthesis (Anderson et al., 2007). 
Extensive side-branching and alveologenesis are induced by the ovarian steroid 
hormone Pg which, in association with the pituitary hormone Prl, promotes the 
differentiation of alveoli (Oakes et al., 2006). Prl stimulates Pg and upregulates the 
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transcription of PgR, and likewise Pg upregulates PrlR. This synergism provides for 
the required levels of both hormones for proper development of the mammary gland. 
Brisken and colleagues found that mammary transplants devoid of PgR in the 
epithelium, but not stroma, lacked side-branching and alveoli (Brisken et al., 1998). 
PrlR-null mammary glands transplanted into Wt pregnant females developed normal 
side branching and produced alveolar buds, but failed to develop lobuloalveolar 
structures (Brisken et al., 1999). Figure 1.2(C-E) depicts schematically the process 
of ductal morphogenesis and lobuloalveolar development. 
Canonical Wnt signalling through β-catenin is one of many mediators that can affect 
PgR-promoted alveologenesis. Constitutive activation of Wnt/β-catenin signalling in 
the luminal cells induced precocious differentiation of lobuloalveoli and resulted in 
adenocarcinomas. Likewise, targeted activation of β-catenin in the basal cells 
induced precocious formation of lateral buds and differentiation of lobuloalveoli 
during pregnancy, increased proliferation during lactation and increased involution 
(Teuliere et al., 2005). In addition, the nulliparous transgenic females in this study 
developed mammary hyperplasia comprised of undifferentiated basal cells and 
reported invasive basal-type carcinomas. In another study, alveologenesis in mice 
null for PgR during gestation can be rescued by activated β-catenin (Hiremath et al., 
2007). Notably, only cells at the tips of ducts were inherently responsive and 
developed alveoli. This is due to the regulation of lineage commitment and cell fate 
mechanisms in the progenitor cells. Interestingly, T helper cell (Th) signalling, 
important for determination of Th1/Th2 cell lineage, is also involved in mammary 
luminal lineage determination and maintenance of the differentiated state of luminal 
cells (Hiremath et al., 2007). 
31 
 
Th2 signalling factors, including signal transducer and activator of transcription 6 
(STAT6), interleukin 4 (IL4), IL13, GATA3 and V-maf musculoaponeurotic 
fibrosarcoma oncogene homolog (c-MAF) have been shown to be involved in luminal 
lineage determination and alveologenesis (Khaled et al., 2007). These Th2 signalling 
factors were found to be up-regulated while, concomitantly, the Th1 signalling factors 
were down-regulated upon induction of differentiation of mammary epithelial cells 
(MEC) towards luminal lineage by a lactogenic cocktail. By day 5 of gestation, 
phosphorylation of STAT6 increases and correlates with the expression of IL4 and 
GATA3 in the epithelium, and later in gestation with c-MAF expression. Also, IL4-/-
/IL13-/- double KO mice and mice lacking the transcription factor STAT6 both show 
about 70% reduction in the numbers of differentiated alveoli which correlates with 
reduced epithelial proliferation (Khaled et al., 2007). On the other hand, precocious 
differentiation of alveoli occurred when the suppressor of cytokine signalling 5 
(Socs5), a negative regulator of STAT6, was deleted. Moreover, conditional deletion 
of GATA3 in alveolar cells during gestation expanded the pool of undifferentiated 
epithelial cells and blocked alveologenesis and lactation, indicating that GATA3 is 
required for alveolar luminal differentiation. Thus, the IL-4/IL13-STAT6-GATA3 Th2 
signalling pathway is important for luminal alveolar lineage. It is worth noting that 
GATA3 is over-expressed in the luminal A subtype of breast cancer (Asselin-Labat et 
al., 2007). 
Canonical Notch signalling is also required for the proliferation of luminal cells, as 
well as for the maintenance, but not establishment, of their differentiated status 
(Buono et al., 2006). The DNA-binding protein RBPJk regulates this signalling 
pathway by binding and repressing promoters of target genes. Upon activation of 
Notch signalling, the Notch intracellular domain (NICD) translocates to the nucleus 
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and binds RBPJk. This releases repression and allows the transcription of target 
genes such as hairy/enhancer-of-split related with YRPW motif protein 1 (Hey1), a 
transcriptional repressor itself. Mice with conditional deletion of RBPJk in mammary 
epithelial cells during pregnancy expressed and accumulated tumour protein p63 in 
their luminal cells, resulting in transdifferentiation to basal type. This was evidenced 
by suppressing of luminal features in favour of inducing more basal characteristics 
including the expression of keratin5. These mutant mice also exhibited increased 
rates of basal cell proliferation (Buono et al., 2006). 
PgR-promoted alveologenesis is also mediated by receptor activator of nuclear 
factor kappa-B ligand (RankL)/nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) pathway, resulting in the transcription of G1/S-specific cyclin-D1 
(Ccnd1). Gestating mammary glands in mice lacking RankL or its receptor Rank 
undergo normal ductal morphogenesis but, later on in pregnancy, do not form 
lobuloalveolar structures, resulting in neonatal death of pups due to lack of milk (Fata 
et al., 2000). The alveolar buds of these mutant mice were characterized by lack of 
proliferation, enhanced cell death and failed activation of protein kinase B (PKB/AKT) 
signalling. RankL co-localises with PgR as the serum levels of the endocrines 
progesterone and estrogen rise in pregnancy. Estrogen synergizes with 
progesterone to increase the transcription of Ccnd1 and thereby increase the rate of 
epithelial cell proliferation and lobuloalveolar development during pregnancy (Said et 
al., 1997). It has also been reported that Ccnd1 levels may be up-regulated through 
insulin growth factor 2 (IGF-2) independent of RankL (Brisken et al., 2002). This 
work revealed that Prl induces IGF-2 expression which in turn induces Ccnd1. All 
three factors are overexpressed in mammary tumours. As already mentioned, the 
ovarian steroid hormones estrogen and progesterone and the pituitary hormone 
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prolactin all synergise to produce a highly proliferated epithelium with differentiated 
lobuloalveoli in preparation for lactation. 
Many genes critical for mammary gland development during early pregnancy were 
revealed through transcript profiling of PrlR-null mammary glands. Two collagen 
members and laminin were identified, which are cell adhesion components of the 
extracellular matrix known to regulate stromal-epithelial interactions crucial for gene 
expression and lobuloalveolar differentiation (Fata et al., 2004). Signalling of these 
molecules may be mediated by the luminal epithelial surface cell receptor “β-1 
integrin”. Conditional ablation of β-1 integrin during early and late gestation revealed 
a critical role in lobuloalveolar formation and functional differentiation. The luminal 
cells detached from the extracellular matrix but remained connected to one another 
and did not undergo apoptosis. Moreover, these mice showed major deficits in milk 
protein and fat synthesis as well as in STAT5 activation, indicating a role in Prolactin 
signalling (Naylor et al., 2005). 
Also identified through transcript profiling of PrlR-null mammary glands were the tight 
junction proteins caludin-3 and claudin-7 which were down-regulated. These play a 
crucial role in the closure of tight junctions that regulate the establishment of cell 
polarity, a process required for proper alveologenesis (Ormandy et al., 2003). 
Connexin-26 (Cx26), a gap junction protein involved in ion and metabolite exchange, 
was also identified in this study. Conditional KO of the Cx26 gene at different stages 
of mammary development showed it to play an essential role in lobuloalveolar 
development as well as in preventing apoptosis of alveoli in early, but not late, 
gestation (Ormandy et al., 2003). 
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Furthermore, all aspects of mammary gland development are crucially mediated by 
the receptor tyrosine kinases of EGFR family and their ligands. The family has four 
known members: EGFR/ErbB/HER1; ErbB2/HER2/Neu; ErbB3/HER3; ErbB4/HER4. 
These are activated by many ligands upon which they dimerize and cross 
phosphorylate to initiate a signalling cascade that has different outcomes depending 
on the ligand and receptors involved (Stern, 2003). Expression of a non-functional 
ErbB2 protein had no effect in transgenic mice till late gestation and postpartum, 
when lactationally active, distended lobuloalveoli did not form (Jones and Stern, 
1999). Mice null for ErbB4 exhibited a phenotype of reduced alveologenesis starting 
at mid-pregnancy and leading to reduced expression of milk genes and failure to 
nurse pups. Investigations of the mammary epithelia revealed reduction of alveolar 
proliferation, lack of functional phosphorylated form of STAT5 and reduced 
expression of β-casein and whey acidic protein (Long et al., 2003). Moreover, mice 
lacking the ErbB4 ligand Neuregulin-α exhibit a similar phenotype to that of ErbB4 
null mice, with attenuated alveolar proliferation and differentiation evidenced by 
dramatic reduction in β-casein expression (Li et al., 2002b). 
Alveolar cell differentiation begins around mid-pregnancy to initiate the secretory 
phase. For full differentiation of lobuloalveoli, a contact between the luminal cells and 
the basement membrane/extracellular matrix is needed (Oakes et al., 2006). This 
contact is enabled by the discontinuity of the myoepithelium around the secretory 
luminal cells. Lobuloalveolar differentiation is marked by the expression of genes 
required for the synthesis and secretion of milk proteins, lactose and lipids. Milk 
secretion is critical to the survival of the newborn mammal as it provides the sole 
nutrients for nourishment. 
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1.2.3.2. Post-lactational involution  
Upon weaning and milk stasis, the lactating mammary gland undergoes an intricately 
coordinated process of epithelial regression, or involution, and returns to a pre-
pregnant state. The involution process occurs through an exquisitely controlled 
program of cell death with concomitant tissue remodelling (Watson and Kreuzaler, 
2011). It involves clearing of the debris of dead cells and milk components upon a 
surge of macrophages and other types of immune cells, degradation of the 
extracellular matrix (ECM), remodelling of the vasculature and re-differentiation of 
adipocytes to regenerate the fat pad. It has been reported that the mammary gland 
microenvironment during involution may promote metastasis of tumourous cells 
(McDaniel et al., 2006). 
Morphologically, the process of involution may be divided into two phases: a first 
reversible phase that extends for approximately 48 hrs in the mouse, and a second 
phase that involves tissue remodelling and recycling of the gland back to the pre-
pregnant state (Watson and Kreuzaler, 2011). In the first phase, the lumens of the 
alveoli become distended due to the accumulation of milk. It also witnesses shedding 
of dying epithelial cells and infiltration of neutrophils. In the second phase, matrix 
metalloproteinases (MMPs) increase their levels and begin to digest the extracellular 
matrix (ECM). Concomitantly, adipocytes re-differentiate, macrophages and other 
immune cells infiltrate and blood vessels and the rest of stromal components 
remodel. Many signalling pathways and genes involved in involution have been 
identified through genetic manipulations of cell lines and living models (mostly mice), 
as well as through transcription profiling studies. 
Involution is triggered mainly by milk stasis, possibly due to a resultant mechanical 
stretch of epithelial cells and/or an accumulation of factors secreted in the milk (Li et 
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al., 1997; Quaglino et al., 2009). Early in involution, the plasma membrane Ca2+-
ATPase (PMCA2) is down-regulated as a result of changes in the shapes of 
mammary epithelial cells. In contrast, the expression of this ion transporter is 
increased several hundred-fold in the apical surface of lactating mammary epithelial 
cells as it transports about 60-70 % of milk calcium (VanHouten et al., 2010). This 
study revealed that mammary epithelial cells devoid of PMCA2 were sensitized to 
apoptosis as a consequence of the elevated intracellular calcium levels. 
Furthermore, the cytokines leukaemia inhibitory factor (LIF) and TGF-β3 are 
secreted factors that have been implicated in involution. LIF was concluded to be a 
physiological activator of STAT3, a transcription factor that is a key mediator of cell 
death in the mammary gland (Kritikou et al., 2003). In this study, phosphorylated 
STAT3 was not observed and its target C/EBP-δ was not up-regulated. Like STAT3-
null mammary glands, LIF-null mammary glands reported delayed involution and 
reduced apoptosis, and unlike Wt glands, showed no up-regulation of insulin-like 
growth factor binding protein 5 (IGFBP5) (Chapman et al., 1999). These glands also 
had increased levels of the pro-apoptotic p53 and p21, most likely as a 
compensatory mechanism for inducing the delayed involution observed. Moreover, 
C/EBP-δ was shown to be a crucial mediator for the expression of some pro-
apoptotic genes in mammary epithelia. Its deletion caused delaying of involution and 
halting of expression of the pro-apoptotic genes coding for p53, Bcl-2 homologous 
antagonist/killer (BAK), IGFBP5 and clusterin/sulphated glycoprotein-2 (SGP2). 
Deletion of C/EBP-δ also prevented the repression of the anti-apoptotic genes 
coding for BFL-1 and Ccnd1 (Thangaraju et al., 2005). Moreover, another STAT3 
target, TGF-β3, was shown to be up-regulated in the mammary epithelium 
immediately after weaning and before cell death, and its expression was found to be 
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induced by milk stasis and not by hormonal cues. Upon milk stasis, TGF-β3-null 
mammary gland transplants showed significant inhibition of cell death relative to wild 
type (Wt) mice (Nguyen and Pollard, 2000). 
Furthermore, delay in involution and remodelling occurred when the NF-kappa B 
upstream regulator “inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β)” 
was conditionally deleted. This phenotype was associated with significant down-
regulation of the death receptor ligands TNF-like weak inducer of apoptosis 
(TWEAK) and tumour necrosis factor (TNF) and the TNF receptor (TNFR1), and with 
prevention of caspase-3 cleavage (Baxter et al., 2006). In addition, many other 
factors involved in apoptosis were shown to contribute to mammary epithelial 
involution. These include the death receptor ligands FasL and TNF-related 
apoptosis-inducing ligand (TRAIL) which are up-regulated during involution, and the 
Bcl-2 family of apoptosis regulators Bcl-2–associated X protein (Bax) and B-cell 
lymphoma 2 (Bcl-2) (Song et al., 2000; Sohn et al., 2001; Schorr et al., 1999; Walton 
et al., 2001). These studies and others suggest the existence of crosstalk between 
these signalling pathways, and that efficient involution and remodelling requires this 
crosstalk to be under tight regulation. 
For involution and remodelling to proceed normally, the dead cells and milk 
components have to be removed. Milk fat globule-EGF factor 8 (MFGE-8) was found 
to play an important role in this process. Mice null for the MFGE-8 glycoprotein 
exhibited reduced phagocytosis, developed inflammation and reported failed 
lactation in subsequent pregnancies (Atabai et al., 2005). Upon completion of 
involution, the lactating mammary gland with massive ductal and lobuloalveolar 
epithelia returns to a pre-pregnant state with minimum epithelia. The mammary 
gland is unique in that most of its development, including its full differentiation, 
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occurs in adulthood, and in that it may repeat its complete development of 
gestation/lactation/involution with cycles of successive pregnancies. 
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1.3. The synuclein family 
The synuclein family includes three highly homologous members that are conserved 
throughout vertebrates. These are α-synuclein, β-synuclein and -synuclein. They 
are heat stable, small, soluble cytoplasmic proteins with an inherently unfolded 
structure, and are expressed mostly in neural tissues (Clayton and George, 1998). - 
and -synucleins are expressed largely in the central nervous system (CNS), while -
synuclein is expressed predominantly, although not exclusively, in the peripheral 
nervous system, in the axons and cell bodies of primary sensory neurons, 
sympathetic neurons and motor neurons (Buchman et al., 1998b). They share 3 
modular domains: a lipid binding domain at a highly conserved N-terminus, a 
hydrophobic central domain and a less conserved acidic C-terminal domain. They 
are also characterized by the absence of cysteines and tryptophans (George, 2002; 
Clayton and George, 1998). Figure 1.3 below shows a diagram illustrating the 
common modular structure in the three highly homologous members. The 
physiological function of the synucleins is not known but they have been shown to 
possess chaperone-like activity (Souza et al., 2000), which points to potential roles in 
the regulation/modulation of some cellular processes through interaction with 
relevant molecules. 
1.3.1. α-synuclein 
α-synuclein is the most widely studied member of this family due to its implication in 
Parkinson’s disease (PD), Alzheimer’s disease (AD), Dementia with Lewy bodies 
disease (DLB), Multiple System Atrophy (MSA) and other neurodegenerative 
diseases. It is linked to PD both genetically and histopathologically. 
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In some affected kindreds, molecular genetic studies established linkage to early-
onset PD by identifying the missense autosomal-dominant point mutations A53T 
(Polymeropoulos et al., 1997), A30P (Kruger et al., 1998) and E46K (Zarranz et al., 
2004), as well as gene dosage duplications (Ibanez et al., 2004; Chartier-Harlin et 
al., 2004) and triplication (Singleton et al., 2004). Moreover, at least four independent 
genome-wide association studies linked single nucleotide polymorphisms (SNPs) in 
α-synuclein gene to the disease (Edwards et al., 2010; Pankratz et al., 2009; Satake 
et al., 2009; Simon-Sanchez et al., 2009). A haplotype spanning about 15.3 kb of the 
α-synuclein gene promoter was also linked to the disease (Pals et al., 2004). 
 
α-syn  MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVH   50 
β-syn  MDVFMKGLSMAKEGVVAAAEKTKQGVTEAAEKTKEGVLYVGSKTREGVVQ   50 
-syn  MDVFKKGFSIAKEGVVGAVEKTKQGVTEAAEKTKEGVMYVGAKTKENVVQ   50 
      
α-syn  GVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQL  100 
β-syn  GVASVAEKTKEQASHLGGAVFS-----------GAGNIAAATGLVKREEF  89 
-syn  SVTSVAEKTKEQANAVSEAVVSSVNTVATKTVEEAENIAVTSGVVRKEDL  100 
      
α-syn  G---KNEEGAPQ--EGILEDMPVDPDNEAYEMPSEEGYQDYEPEA-      140 
β-syn  PTDLKPEEVAQEAAEEPLIEPLMEPEGESYEDPPQEEYQEYEPEA-      134 
-syn  R------PSAPQ------------QEGEASKE-KEEVAEEAQSGGD      127 
 
Figure 1.3. Aligned sequences of human α-, β- and -synucleins using Clustalw2 
software. Red letters indicate differences from α-synuclein sequence. Light and dark 
grey-boxed sequences represent the imperfect 11 amino acid repeats containing the 
consensus KTKEGV (of note is the absence in β-synuclein of an imperfect repeat in 
the NAC peptide region). The underlined region marks the highly hydrophobic central 
NAC region. Negatively charged amino acids in the acidic C-terminal tail are 
highlighted in yellow. The UniProtKB/Swiss-Prot accession numbers for α-, β- and -
synucleins are P37840.1, Q16143.1 and O76070.2, respectively. Assignment of 
repeat motifs and NAC region is based on Sung, et al 2007. 
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1.3.1.1. α-synuclein structure 
α-synuclein was first isolated from the pacific electric ray fish Torpedo californica 
using antisera raised against purified cholinergic synaptic vesicles. Expression 
screening of a cDNA library constructed from the electromotor nucleus resulted in 
the isolation of a cDNA clone encoding a 143 amino acid protein of an approximately 
17 kDa size. This protein localized to the inner nuclear envelope and presynaptic 
nerve terminals and was hence named synuclein (Maroteaux et al., 1988). Also, this 
group used the same antisera to screen and isolate from a rat brain cDNA library a 
clone that coded for a highly homologous 140 amino acid protein. In humans, the α-
synuclein orthologue was first isolated as the precursor of the non-amyloid 
component of AD amyloid plaque (NACP) (Ueda et al., 1993). The brain cDNA 
library was screened and a cDNA was cloned encoding a protein of approximately 
19 kDa. 
Maroteaux’s group analysis of the electric rays’ α-synuclein revealed the presence of 
an 11 amino acid imperfect repeat motif within the N-terminal 93 amino acids. This 
motif repeated 6 times and contained the consensus sequence KTKEGV. The motif 
region is conserved in the synuclein family and is similar to the apolipoprotein class-
A2 helix. It is believed to endue the synucleins with a reversible phospholipid–
binding property, a characteristic that supports a role for α-synuclein in presynaptic 
vesicle release (Clayton and George, 1998). Indeed, using site-directed 
mutagenesis, the in vitro binding of -synuclein to phospholipid vesicles was shown 
to involve the N-terminal repeat domain. Notably, the binding induced a large shift in 
secondary structure from about 3% to nearly 80% -helix, a finding that lent further 
strength to the proposed role in presynaptic function (Perrin et al., 2000; Davidson et 
al., 1998). The protein is found enriched at presynaptic nerve terminals and 
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particularly in the synaptic vesicle fraction of various brain neurons, including 
neurons of the hippocampus, amygdala, olfactory tubercle, striatum, thalamus and 
cerebral cortex (Giasson et al., 2001; Iwai et al., 1995; Li et al., 2002a; Mori et al., 
2002). 
Unlike the N-terminus, the C-terminus tail is the least conserved between the 
synuclein members and contains many acidic amino acids. It is believed to acquire 
no secondary structure when the protein is lipid-bound. The more hydrophobic 
central region contains the 35-amino acid-NAC peptide which is thought to render 
the protein susceptible to aggregation (Maroteaux et al., 1988; Clayton and George, 
1998; Lavedan, 1998). The α-synuclein-encoding gene was mapped to chromosome 
4q21.3-q22 and was shown to have 6 exons, 5 of which are coding (Spillantini et al., 
1995; Chen et al., 1995; Touchman et al., 2001). Three human isoforms of α-
synuclein have been described as a result of alternative splicing (Xia et al., 2001). 
1.3.1.2. α-synuclein function. 
The physiological function of α-synuclein, as well as β- and -synuclein, is not clear 
yet, but it has been proposed to play a role in the regulation of synaptic vesicle 
release and plasticity (Clayton and George, 1998; Lavedan, 1998), in the 
biosynthesis and metabolism of dopamine (Al-Wandi et al., 2010; Lee et al., 2001; 
Perez et al., 2002) and in promoting the assembly of N-ethylmaleimide–sensitive 
factor attachment protein receptor (SNARE) complexes, proteins mediating vesicle 
fusion with the cell membrane (Burre et al., 2010). 
Of the early findings pointing to a role for α-synuclein in the regulation of synaptic 
vesicle release and plasticity is a study by Jenco and co-workers (Jenco et al., 
1998). They purified from a bovine brain a factor that inhibited phospholipase D2 
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activity in vitro, which appeared to be a mixture of α- and β-synucleins. 
Phospholipase-D is known to be involved in the production of phosphatidic acid, 
which is thought to be a key factor in the synthesis and fusion of synaptic vesicles. 
Further probing into the function of α-synuclein found structural and functional 
homology with the 14-3-3 proteins, a family of chaperones that are, like α-synuclein, 
abundant in the cytoplasm of neurons (Ichimura et al., 1988; Ostrerova et al., 1999). 
This prompted the investigation of α-synuclein for binding 14-3-3 as well as proteins 
known to bind 14-3-3 proteins. 
Immunoprecipitation studies using homogenized rat brain tissue demonstrated that 
α-synuclein is associated with 14-3-3 proteins. It also bound protein kinase C (PKC) 
and inhibited its activity, but did not affect its translocation to the cell membrane 
(Ostrerova et al., 1999). This study also demonstrated that, in rat cortex homogenate 
and HEK 293 cells, α-synuclein protein associated with the extracellular-regulated 
kinase (ERK) and dephosphorylated Bcl2-associated death promoter (BAD), 
suggesting a possible role in regulating ERK cascade and apoptosis. Moreover, 
over-expressing the wild type or mutant A53T or A30P α-synuclein proteins in HEK 
293 cells resulted in cytotoxicity and induced apoptosis, with the mutant proteins 
having a much more pronounced effect. 
Furthermore, α-synuclein was investigated for physical association and functional 
relation to the tyrosine hydroxylase (TH), the rate-limiting enzyme in the biosynthesis 
of dopamine (DA) (Ichimura et al., 1988). α-synuclein was found to co-
immunoprecipitate with TH from homogenates of rat striatum and MN9D 
dopaminergic cells (Perez et al., 2002). Immunoelectron microscopy on MN9D cells 
confirmed co-localization of α-synuclein with TH on or near mitochondria and 
vesicular membranes. To probe the functional aspect of this association, authors 
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over-expressed α-synuclein in MN9D cells and demonstrated a significant reduction 
in TH activity accompanied by a decrease in DA levels. The reduced TH activity was 
shown to result from a reduced level of phosphorylated enzyme rather than reduced 
total TH levels or increased DA degradation (Perez et al., 2002). This reduced 
phosphorylation may be due to α-synuclein interacting with TH thereby 
inhibiting/reducing a kinase’s ability to phosphorylate TH, or inducing/enhancing a 
phosphatase enzyme to remove added phosphates. 
Another evidence for a role for α-synuclein in DA metabolism came from studies of 
α-synuclein interaction with the human presynaptic dopamine transporter (hDAT). 
hDAT is a presynaptic transmembrane protein known to mediate the reuptake of DA 
upon release at the synaptic terminals of substantia nigral neurons. Using the yeast 
two hybrid system, this interaction was shown to involve the NAC domain of α-
synuclein and the C-terminus of hDAT. Immunoprecipitation showed this binding to 
occur in both rat striatum and Ltk- cells co-transfected with plasmids expressing 
human α-synuclein and hDAT. Also, confocal immunofluorescent microscopy 
confirmed co-localization of the two proteins in cultured human precursor cells of 
substantia nigra neurons. Further investigation of the co-transfected Ltk- cells 
revealed that the binding facilitates clustering of DAT at the cell membrane surface 
and thereby accelerates the rate of cellular DA uptake (Lee et al., 2001). 
The implication of α-synuclein in DA metabolism was further supported by 
observations made on α-synuclein knockout (KO) mice (Abeliovich et al., 2000). 
These mice were viable, fertile, displayed no severe morphological or histological 
abnormalities, and showed a normal complement of dopaminergic neurons. 
However, they showed increased release of dopamine at the nigrostriatal 
presynaptic terminals when paired electrical stimuli were applied. Concurrent with 
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this altered DA release, striatal dopamine content was lower (by about 18%) and DA-
dependent locomotor response to amphetamine was attenuated compared to the Wt 
littermates. Accordingly, the authors postulated that α-synuclein may act as a 
presynaptic negative regulator of DA neurotransmission. 
However, a later study conducted by Cabin and co-workers did not find any 
difference in amphetamine-induced locomotor response between Wt and α-synuclein 
KO mice (Cabin et al., 2002). This discrepancy may be due to background strain 
differences as it has been reported that different strains may respond differently to 
amphetamine (Ralph et al., 2001). This same study, however, reported significant 
impairments in hippocampal synaptic response following prolonged, repetitive 
electrical stimulation. Closer investigation revealed ultrastructural differences where 
the number of reserve-resting pool of synaptic vesicles in the hippocampus was 
significantly reduced in the KO mice, as well as in cultured hippocampal neurons 
obtained from 17.5 day post coitum KO embryos (Cabin et al., 2002). Similar 
ultrastructural difference was also observed in cultured rat primary hippocampal 
neurons in which α-synuclein levels were down-regulated by about 50% using 
antisense oligonucleotides (Murphy et al., 2000). 
Further discrepancy was added by results obtained in studies of α- and β-synuclein 
double-KO mice (α/β-synuclein KO) (Chandra et al., 2004). These mice showed 
normal basic brain function and normal survival. Moreover, unlike some of the above 
data, no changes in the ultrastructure of synapses and no decrease in the size of 
synaptic vesicle pools were found. Nevertheless, authors recorded a statistically 
significant 18% reduction in brain striatal dopamine levels compared to Wt mice, 
whereas the α- and β-synuclein single-KOs had only slight reductions compared to 
the Wt mice. This hinted towards functional redundancy in maintaining normal 
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dopamine levels in the striatum. Nevertheless, the reduced levels of dopamine did 
not result in any significant alterations in the release and reuptake of the 
neurotransmitter. In addition, quantitative alterations in four small synaptic proteins 
were reported: about 50% increase in -synuclein, 30% increase in 14-3-3-ζ, 30% 
reduction in 14-3-3-ε and 30% reduction in complexin proteins. These alterations 
may reflect functional relationships between these proteins and α and β-synucleins: 
up-regulation of the homologous family member -synuclein may serve a 
compensatory role; 14-3-3 proteins are known to interact with synucleins (Ostrerova 
et al., 1999); complexins regulate neurotransmitter release by binding to assembled 
soluble N-ethylmaleimide–sensitive factor attachment protein receptor (SNARE) 
complexes, proteins mediating vesicle fusion with the cell membrane (Brose, 2008; 
Reim et al., 2001). 
Indeed, α-synuclein was shown, both in vivo and in vitro, to bind synaptic vesicle-
associated membrane protein 2 (VAMP2)/synaptobrevin-2 and promote SNARE 
complex assembly (Burre et al., 2010). Furthermore, age-dependent neurological 
deficits exhibited by α-/β-/-synuclein triple-KO mice were characterized by 
decreased SNARE complex assembly and resulted in premature death of the mice. 
This led to the conclusion that the synucleins may provide chaperoning activity 
required for maintaining SNARE complex assembly during increased synaptic 
activity, synaptic injury and aging (Burre et al., 2010). In an earlier study, transgenic 
overexpression of α-synuclein unexpectedly rescued cysteine-string protein alpha 
(CSP-α) KO mice from progressive lethal neurodegeneration, while ablation of the 
endogenous α-synuclein gene accelerated this process. CSP-α is an abundant 
synaptic protein thought to have co-chaperoning activity essential for neuronal 
survival. Deletion of CSP-α induces neurodegeneration by compromising proper 
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SNARE complex assembly and consequently neurotransmitter release, and it has 
been suggested that transgenic overexpression of α-synuclein partially corrected 
formation of these complexes by acting downstream of CSP-α (Chandra et al., 
2005). It has also been demonstrated that for rescuing this type of 
neurodegeneration α-synuclein should be able to bind phospholipids of synaptic 
vesicle membranes. However, in another study no changes in SNARE complex 
assembly were observed in the striatum of triple-KO mice, suggesting that in 
dopaminergic synaptic terminals the loss of α- and other synucleins function can be 
efficiently compensated (Anwar et al., 2011). 
1.3.2. β-synuclein 
1.3.2.1. β-synuclein structure 
β-synuclein was initially isolated from bovine brain as a 134 amino acid residue 
phosphoneuroprotein-14 (PNP-14), and found to be phosphorylated on serine 
residues by Ca2+ calmodulin-dependent protein kinase II (Nakajo et al., 1990; Nakajo 
et al., 1993). The human orthologue was later identified and found to have 61% 
sequence homology with the 140 amino acid long α-synuclein, and was therefore 
renamed β-synuclein (Jakes et al., 1994). It shares with the other two members, α- 
and -synucleins, the three modular domains shown above in Figure 1.3 with a 
deletion of 11 amino acids overlapping the last repeat motif occurring within the 
hydrophobic NAC region. This renders it, relative to α- and -synucleins, less 
predisposed to forming secondary alpha helical structures in this part of its lipid 
binding domain, more prone to extending structures at the acidic tail, and thus less 
prone to aggregation (Sung and Eliezer, 2007). The β-synuclein gene has been 
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mapped to chromosome 5q35, with 6 exons, five of which are coding (Spillantini et 
al., 1995). 
1.3.2.2. β-synuclein function 
Like α- and -synuclein, the physiological function of β-synuclein is still eluding. The 
pattern of expression is very similar to that of α-synuclein, being predominantly 
expressed in the CNS and enriched at presynaptic terminals (Jakes et al., 1994). 
This co-expression points to some degree of functional redundancy. 
As mentioned above, Jenco and co-workers purified from a bovine brain a factor that 
inhibited phospholipase D2 activity in vitro. This factor was analysed to be a mixture 
of α- and β-synucleins (Jenco et al., 1998). Phospholipase D is known to be involved 
in the production of phosphatidic acid, a factor thought to be involved in the 
synthesis and fusion of synaptic vesicles. Thus, β-synuclein may be involved in the 
synthesis and fusion of synaptic vesicles, suggesting some functional redundancy 
with α-synuclein. β-synuclein may also be involved in dopamine synthesis, as 
evidenced in Chandra’s group observations on α-/β-synuclein double-KO mice 
summarized above (Chandra et al., 2004): these mice recorded a statistically 
significant 18% reduction in brain striatal dopamine levels compared to Wt mice, 
whereas the α- and β-synuclein single-KOs had only slight reductions compared to 
the Wt mice. This indicates functional redundancy in maintaining normal dopamine 
levels in the striatum. 
Interestingly, β-synuclein has been reported to have a cell protecting role against 
cytotoxicity induced by α-synuclein aggregation. It was found to inhibit the protofibril 
formation of α-synuclein in vitro (Park and Lansbury, 2003), and to completely inhibit 
α-synuclein fibril formation, as was -synuclein, at a 4:1 molar excess ratio (Uversky 
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et al., 2002). Moreover, human (h) α-/β-synuclein double transgenic mice show 
ameliorated motor deficits and reduced hα-synuclein aggregation in the brain 
compared to hα-synuclein monotransgenic ones (Hashimoto et al., 2001). This work 
also demonstrated that α- and β-synuclein co-immunoprecipitated in the brains of 
double transgenics as well as when co-expressed in HEK 293 cells, and that β-
synuclein inhibited the aggregation of α-synuclein in vitro. This suggested that β-
synuclein may act as a chaperone negative regulator of α-synuclein fibrillation and 
aggregation, and thus protects against cytotoxicity and neurodegeneration. 
1.3.3. -synuclein 
1.3.3.1. -synuclein structure 
 -synuclein is the last to be discovered and the least studied member of the 
synuclein family. Its gene was independently identified by several laboratories in rat, 
mouse and human genomes (Akopian and Wood, 1995; Buchman et al., 1998b; Ji et 
al., 1997; Lavedan et al., 1998). One group named it breast cancer-specific gene1 
(BCSG1) because it was found to be aberrantly expressed in a large percentage of 
advanced infiltrating breast carcinomas, compared to normal tissue and benign 
tumours where its levels were absent or hardly detectable (Ji et al., 1997). Other 
groups called it synuclein-like protein (Akopian and Wood, 1995; Lavedan et al., 
1998) or persyn (Buchman et al., 1998b). The gene maps to chromosome 10q23.2-
q23.3, spans about 5.0 Kb, is composed of five exons all of which are coding and 
transcribes into approximately 1.0 Kb mRNA (Lavedan, 1998; Ninkina et al., 1998). 
The human protein is 127 amino acids long, shows 56% and 54% sequence identity 
with - and -synuclein, respectively, and was therefore renamed -synuclein 
(Lavedan et al., 1998; Clayton and George, 1998). The -synuclein protein shares 
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the family’s three modular domain structure mentioned above and shown in Figure 
1.3. It is the least conserved of the family members and is largely divergent at the 
acidic C-terminal domain where it notably lacks the tyrosine-rich signature of - and 
-synucleins. -synuclein has a free-state residual secondary structure similar to that 
of -synuclein, accounting for the tendency of both proteins to aggregate in vitro and 
form fibrils. However, the transient lipid-bound structure of -synuclein is more 
comparable to that of -synuclein. This underlies the ability of both proteins to 
prevent the aggregation of -synuclein, albeit -synuclein is much more efficient at 
this due to its more extended structure in the NAC region caused by the 11 amino 
acid deletion (Sung and Eliezer, 2007). 
1.3.3.2. -synuclein tissue distribution and subcellular localization 
-synuclein is expressed predominantly, although not exclusively, in the peripheral 
nervous system, in the axons, presynaptic terminals and to less extent in cell bodies 
of primary sensory neurons, sympathetic neurons and motor neurons (Buchman et 
al., 1998b). It is highly expressed in certain areas of the central nervous system 
including the substantia nigra, thalamus, subthalamic nucleus, caudate nucleus, 
hippocampus, amygdala, and retina and is moderately expressed in the corpus 
callosum (Surguchov et al., 1999; Lavedan et al., 1998). Furthermore, it was shown 
to be expressed in the stratum granulosum of neonatal and adult mice epidermis 
(Ninkina et al., 1999). It is also highly expressed in cells of the wall of small diameter 
blood vessels (see below). Low levels of expression were also detected in heart, 
skeletal muscle, pancreas, kidney, lung, testis, ovary and colon (Ji et al., 1997; 
Lavedan et al., 1998), but these results might reflect expression of this gene in 
neurons of the autonomic nervous system and in cells of the wall of small diameter 
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blood vessels. -synuclein is also expressed in adipocytes of subcutaneous and 
visceral fat where it is found to be overexpressed in obese people (Oort et al., 2008) 
and adipocytes of the mouse mammary gland, as will be shown later in this work. 
To reveal domains responsible for subcellular localization, recombinant deletion 
mutants of - and -synucleins were expressed as fusion proteins with enhanced 
green fluorescent protein (eGFP) in hippocampal neurons (Specht et al., 2005). The 
results showed that the N-terminal and core region of -synuclein directed 
presynaptic targeting and caused nuclear exclusion, whereas the C-terminal domain 
supported nuclear localization. In -synuclein, the more conserved N-terminal 
domain favoured cytoplasmic localization as in -synuclein, but the divergent C-
terminal domain did not support nuclear localization. However, another group using 
neuronal and nonneuronal cells from ocular tissue concluded that -synuclein has a 
dynamic localization and may associate with subcellular structures (Surguchov et al., 
2001). By immunocytochemical staining, they showed that in primary human optic 
nerve astrocytes, bovine retinal epithelial cells and human retinoblastoma Y79 cells 
during the interphase, -synuclein localized to the perinuclear space and bound to 
centrosomes. They also found the protein bound to the spindle poles in the mitotic 
Y79 cells. In human astrocytoma cell line U373 and melanoma cells OM431 and 
C8161, the protein was observed to lose the association with centrosomes and 
redistribute to the midbody in the telophase. This group also showed that, in mouse 
photoreceptor cell line 661W and human melanoma cells OM431 and C8161, stress 
conditions (incubation at 42C for 12 hrs) effected translocation of -synuclein to the 
nucleus (Surgucheva et al., 2006). 
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1.3.3.3. -synuclein function 
Like α-synuclein and β-synuclein, the physiological function of -synuclein is still 
elusive but it has been associated with some cellular processes including 
chaperone-like activity (Souza et al., 2000), regulation of neurofilament network 
integrity (Buchman et al., 1998a), regulation of microtubules (Zhang et al., 2010), cell 
division and cytokinesis (Surgucheva et al., 2006), regulation/modulation of some 
signalling pathways (Golebiewska et al., 2012; Surguchov et al., 1999; Surguchov et 
al., 2001), energy homeostasis and obesity (Guschina et al., 2010; Oort et al., 2008), 
and progression of cancer (Ahmad et al., 2007; Hibi et al., 2009; Ji et al., 1997). 
1.3.3.3.1. -synuclein possesses chaperone-like activity 
-synuclein, as well as α- and  β-synucleins, were shown to possess chaperone-like 
activity. They prevented the thermally-induced aggregation of alcohol 
dehydrogenase at 45C and the chemically-induced aggregation of insulin at 25C, 
two assays routinely used in the determination of chaperone-like activities of proteins 
(Souza et al., 2000; Smulders et al., 1996; Manna et al., 2001). As mentioned above, 
one interesting role proposed for -synuclein and especially β-synuclein is the 
inhibition of α-synuclein fibrillation in vivo, acting effectively as chaperones to 
minimize the aggregation of α-synuclein. This is thought to occur through the 
incorporation of -synuclein and β-synuclein into the forming α-synuclein 
intermediates resulting in their stabilization, as it is these partially folded intermediate 
structures that are believed to lead to fibrillation (Uversky et al., 2002). The 
possession of such chaperone-like activity points to a potential role in the 
regulation/modulation of some cellular processes through interaction with relevant 
molecules. 
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1.3.3.3.2. -synuclein and regulation of the cytoskeleton 
A role in the regulation of neurofilament network was postulated for -synuclein 
(Buchman et al., 1998a). This conclusion was drawn when -synuclein 
overexpression in cultured trigeminal ganglion neurons resulted in a dramatic 
decrease in the levels of neurofilaments (NF) fluorescence staining. 
Immunofluorescent staining of other cytoskeletal filaments, namely microfilaments, 
microtubules and peripherin, did not exhibit any changes. The effect on 
neurofilaments was largely suppressed by the addition of calpeptin, an inhibitor of 
Ca2+-dependent proteases. Western blotting revealed NF-H to be degraded, but not 
NF-M, NF–L or the intermediate protein peripherin. This observation suggested that 
-synuclein might have a role in the regulation of neurofilament network integrity 
through increasing the susceptibility of NF-H to Ca2+-dependent proteases 
(Buchman et al., 1998a). 
Nevertheless, another study reported a role for -synuclein in the regulation of 
microtubules (Zhang et al., 2010). In vitro assays demonstrated that -synuclein 
promoted tubulin polymerization and bound to preformed microtubules. It also 
reduced the aggregation of small microtubule bundles induced by microtubule-
associated protein 2 (MAP2) and promoted longer and thicker bundles of 
microtubules in a dose-dependent manner. This binding of -synuclein to 
microtubules was also confirmed in vivo, in human breast cancer cell line T47D and 
HeLa cells. Using immunocytochemistry, -synuclein was shown to colocalize with 
microtubules in HeLa cells and to reduce the aggregation and rigidity of microtubule 
bundles promoted by paclitaxel. It was also found to cause microtubule-dependent 
clustering of mitochondria in the perinuclear space in the ovarian cancer cell line 
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A2780. Thus, -synuclein, at least under certain cellular conditions, may act as a 
microtubule-associated protein that regulates microtubule-related cellular processes 
such as trafficking of mitochondria and vesicles (Zhang et al., 2010), cell division and 
cytokinesis (Surgucheva et al., 2006) and, if aberrantly expressed, increases 
resistance of cancer cells to apoptosis induced by anti-microtubule drugs such as 
paclitaxel and vinblastine (Zhou et al., 2006; Pan et al., 2002). 
1.3.3.3.3. -synuclein and signal transduction 
-synuclein has been shown to modulate key molecules involved in signal 
transduction. Overexpression of the protein in the retinoblastoma Y79 cell line led to 
significant increases in the levels of both isoforms of mitogen-activated protein 
kinase (MAPK), Erk1 and Erk2, as well as the levels of the phosphorylated form of 
the coactivator, transcription factor (TF) Elk1 (Surguchov et al., 2001; Surguchov et 
al., 1999). Using fluorescence-activated cell sorting (FACS) analysis of cell cycle 
progression, Y79 cells overexpressing -synuclein exhibited a greater percentage of 
cells in the G2/M phase and a corresponding lower percentage in the G1 phase. Y79 
cells overexpressing -synuclein were also confirmed to have a higher percentage of 
cells undergoing mitosis by cell counting upon staining with anti-α-tubulin antibody. 
In search of other transcription factors as targets of -synuclein, TransSignal TF 
Protein Arrays (Panomics) were used to detect possible in vitro binding of the protein 
to some TFs (Surgucheva and Surguchov, 2008). This resulted in the identification of 
the following potential targets: JunB, methyl CpG binding protein 2 (MECP2), c-AMP 
responsive element binding protein 1 (CREB-1), peroxisome proliferator-activated 
receptor-gamma (PPAR), transcription elongation factor A protein 1 (TCEA1) and 
55 
 
activating transcription factor 3 (ATF3). Some of these will be discussed later in 
connection with mammary gland tumourigenesis and adipocytes. 
The involvement of the synuclein proteins in signal transduction extends to G 
protein-coupled receptor (GPCR) signalling pathways. All three synucleins were 
found to be in vitro substrates for different types of GPCR kinases (GRK) (Pronin et 
al., 2000). In the presence of phospholipids, the GRK5 isozyme produced a 
phosphorylation pattern that reduced the electrophoretic mobility of -synuclein. This 
was detected as two heavier, additional bands in the western blot. Mutation of serine 
124 abolished the lighter band while the two heavier ones associated with 
phospholipids’ addition remained. This suggests that GRK5 phosphorylates -
synuclein in at least another site. This study by Pronin et al further reported that 
GRK2 and GRK5 were also able to phosphorylate α-synuclein in vivo. 
Furthermore, -synuclein may modulate G proteins signalling through interaction with 
phospholipase Cβ2 (PLCβ2) (Golebiewska et al., 2012). G proteins activate PLC 
which in turn catalyses the hydrolysis of Phosphatidylinositol 4,5-bisphosphate 
(PIP2) into the two second messengers diacylglycerol (DAG) and inositol 1,4,5 
trisphosphate (IP3). IP3 may then diffuse into the cytosol and bind calcium channels 
in the endoplasmic reticulum (ER) and cause the release of Ca2+. This released Ca2+ 
allows DAG to activate PKC, leading to further signal transduction and eventual 
changes in cellular processes depending on incoming signal and cell type. In this 
study, -synuclein co-immunoprecipitated and colocalized with PLCβ2 in two cultured 
breast cancer cell lines, MCF10A and MDA-MB-231. This cellular association of the 
two proteins was confirmed in vitro and found to involve the C-terminal region of 
PLCβ2. Functionally, this interaction was shown to inhibit the in vitro enzymatic 
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activity of PLCβ2 as evidenced by a 4-fold decrease in the production of IP3 from 
PIP2 hydrolysis. This enzymatic inhibition was thought to result from inhibition of 
product release through stabilizing a conformation of PLCβ2 that binds the product 
more strongly. The activated G proteins Gαq and Gβ bind to PLCβ2 and relieve the 
inhibition by -synuclein and thus activate the enzyme. The inhibition of PLCβ2 by -
synuclein is thought to have no significant cellular effects as the basal enzymatic 
activity of the enzyme is low. However, it may serve to create a more robust effect as 
the G proteins both release the inhibition of basal activity and at the same time 
activate the stimulated activity of PLCβ2 (Golebiewska et al., 2012). 
1.3.3.3.4. -synuclein and modulation of monoamine transporters  
There is growing body of evidence that synucleins may play a role in monoamine 
homeostasis including synthesis, release and reuptake (Oaks and Sidhu, 2011). 
Knocking down of endogenous -synuclein in the nucleus accumbens of 
experimental Wistar rats reduced the locomotor response to cocaine by about 47% 
compared to control animals, whereas overexpression of the protein had no effect. 
On the other hand, overexpressing the protein along with DAT increased the 
cocaine-induced locomotor response by about 52%. This led to the conclusion that -
synuclein and DAT exert a synergistic effect, possibly through a direct interaction 
between the two proteins (Boyer and Dreyer, 2008). 
Moreover, -synuclein was implicated in the modulation of norepinephrine transporter 
(NET). It was found to be upregulated and α-synuclein to be concomitantly 
downregulated in the frontal cortex of an animal model of depression, Wistar-Kyoto 
(WKY) rats, compared to control parent strain Wistar. This was believed to result in 
altered interactions with NET and microtubule cytoskeleton, leading to the observed 
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reduction in cell membrane-surface NE levels. However, chronic treatment with the 
NET-selective antidepressant Desipramine reduced -synuclein levels while 
increased α-synuclein and NET levels. In addition, synaptosomes prepared from 
frontal cortex of WKY rats showed no sensitivity to the microtubule-destabilizing drug 
nocodazole, possibly due to the increased expression of -synuclein as it has been 
known to effect resistance of cancer cells to such chemotherapeutic drugs (Inaba et 
al., 2005). However, treatment of synaptosomes from Desipramine-treated WKY 
experimental rats with nocodazole led to increased [3H]-NE uptake. Taken together, 
these results suggest a role for both - and α-synucleins in the modulation of NET 
trafficking, with a possible baseline optimal ratio to maintain normal NET cell 
membrane levels. The authors also postulated that, contrary to α-synuclein, -
synuclein negatively modulates NET trafficking in a microtubule-independent manner 
(Jeannotte et al., 2009). 
-synuclein was also found to negatively modulate serotonin transporter (SERT) 
(Wersinger and Sidhu, 2009). In this study, co-immunoprecipitation showed - or α-
synuclein to complex with SERT, a finding confirmed by immunocytochemistry 
showing colocalization of either synuclein with SERT in rat primary raphae nuclei 
neurons. Cotransfection of Ltk- cells with either - or α-synuclein and SERT results in 
the reduction of [3H]-SER uptake compared to transfection with SERT alone. This 
reduced SERT reuptake activity was partial in the case of -synuclein, with about 
27% maximal reduction in activity even at increasing expression levels of -
synuclein. α-synuclein, on the other hand, reduced SERT activity by about 65% at 
the expression level matching that for -synuclein. Thus, -synuclein may exert a 
partial negative modulation on SERT distribution to the cell membrane and activity. 
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1.3.3.3.5. -synuclein and lipid metabolism 
-synuclein was postulated to play an important role in adipocyte physiology (Oort et 
al., 2008). Its mRNA levels were significantly upregulated in mature 3T3-L1 
adipocytes compared to trace levels found in preadipocytes, suggesting a role in the 
physiology/maintenance of the differentiated state. Short term treatment (18 h) of 
fully mature 3T3-L1 adipocytes with the peroxisome proliferator-activated receptor-
gamma (PPAR) agonist GW1929 reduced -synuclein mRNA levels by about 50%. 
This reduction was qualitatively paralleled by leptin mRNA expression levels, 
suggesting that the respective genes may share PPAR response elements that 
repress the genes upon PPAR activation in adipocytes. Moreover, -synuclein 
mRNA levels were found to be differentially upregulated in white adipose tissue 
(WAT) from obese versus nonobese subjects from different groups, and was higher 
in subcutaneous (SC) than visceral adipose tissue (VAT). Again, leptin mRNA levels 
were changed co-ordinately with levels of -synuclein mRNA, with a Pearson 
correlation coefficient of 0.887. Also, WAT -synuclein mRNA levels were 
downregulated upon a 3 week-fasting regimen in obese individuals (Oort et al., 
2008). This data points to a role for -synuclein in fat metabolism and adipocyte 
physiology. 
The fact that -synuclein is strongly expressed in both WAT (adipocytes) and the 
peripheral nervous system hints to the sharing of some functional pathways in these 
two different tissues. A role for -synuclein in lipid metabolism in the nervous system 
was suggested by observations in -synuclein KO mice (Guschina et al., 2010). In 
these mice, lipid composition was examined in two brain regions, midbrain and 
cerebral cortex that normally have high and substantially lower -synuclein 
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expression levels, respectively. Compared to Wt mice, -synuclein KO mice reported 
a significant increase in the relative proportion of phosphatidylserine (PtdSer) in the 
midbrain region, but not in the cerebral cortex in which the relative proportions of 
membrane polar lipids were unchanged. Moreover, alterations in fatty acid patterns 
were reported in the cerebral cortex of KOs where the levels of docosahexaenoic 
acid (DHA) in PtdSer and phosphatidylethanolamine (PtdEtn) were modified. PtdSer 
and DHA are known to have important roles in cell signalling, apoptosis, enzyme 
regulation, SNARE complex formation and function of acetylcholine receptor, among 
others (Mozzi et al., 2003; Walczewska et al., 2011). Therefore, -synuclein may play 
an indirect role in such vital neuronal processes through modulation of lipid 
metabolism and phospholipid fatty acid composition. 
1.3.3.3.6. -synuclein and diet-induced obesity  
A role for -synuclein in diet-induced obesity was investigated in this lab (Millership et 
al., 2012). Unless otherwise referenced, this section summarizes some of the 
findings from a PhD project undertaken at this lab by Steven Millership and 
supervised by Prof. Vladimir Buchman. In this study, -synuclein KO and Wt mice 
were used to study a role of this protein in the development of high fat diet (HFD)-
induced obesity. As in obese people, in Wt C57Bl6J mice WAT -synuclein 
expression was nutritionally regulated - the HFD-fed mice exhibited increased mRNA 
and protein levels compared to the control low fat diet (LFD)-fed mice. This increase 
could be reversed upon fasting or changing to LFD. Moreover, expression of -
synuclein was restricted to the mature adipocytes and localized to the cytosol but not 
the lipid droplets. It has also been demonstrated that -synuclein is not required for 
adipocyte differentiation as the KO mice developed mature WAT adipocytes. This 
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has been confirmed in experiments with mouse embryonic fibroblasts (MEF) isolated 
from KO and Wt mice that revealed no effect of -synuclein expression on 
differentiation of preadipocytes in vitro, as cells of both genotypes differentiated into 
adipocytes with similar efficiencies and kinetics. 
However, the ablation of -synuclein protected mice from HFD-induced obesity and 
associated metabolic disturbances. The HFD-fed KO mice gained only 16% of their 
original body weight compared to a 33% weight gain in the HFD-fed Wt mice, with no 
difference observed in weight between Wt and KO mice fed LFD. This attenuated 
weight gain was at least partly attributed to the reduced adipocyte hypertrophy as the 
KO mice accumulated less WAT that was characterized by smaller size adipocytes 
compared to adipocytes in HFD-fed Wt mice. 
The HFD-fed KO mice were also protected from metabolic disturbances associated 
with obesity. Plasma insulin levels were only increased in the HFD-fed Wt mice (~3 
fold increase), with the HFD-fed KO mice retaining similar levels to those in the LFD-
fed mice. Likewise, hepatic and plasma Triacylglycerol (TAG) levels were only 
increased in the HFD-fed Wt mice, with the HFD-fed KO mice retaining similar levels 
to those in the LFD-fed mice. Also, no steatosis was observed in the liver of the 
HFD-fed KO mice. However, in contrast to mice on LFD, both KO and Wt mice on 
HFD reported increased plasma leptin levels, but less significantly so in the KO mice 
(~2.9 fold increase versus ~5.5 fold increase, respectively). In addition, the HFD-fed 
KO mice exhibited increased whole-body lipid utilization and energy expenditure, 
with increased lipid oxidation and reduced carbohydrate oxidation compared to the 
HFD-fed Wt mice. 
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The decreased lipid storage and increased lipid utilization mentioned above in the 
HFD-fed KO mice were suggested to be due to increased lipolytic capacity of WAT 
adipocytes lacking -synuclein. This suggestion was supported by the increased 
levels of non-esterified fatty acids (NEFA), as well as ~1.8 fold increase in the protein 
levels of adipose triglyceride lipase (ATGL) observed in epididymal WAT of the HFD-
fed KO mice. Also, this tissue displayed ~1.9 fold increase in the protein levels of 
phosphorylated extra cellular regulated kinase (ERK, Thr202/Tyr204), a key protein 
kinase intracellular signalling molecule in the ERK signalling pathway involved in 
many basic cellular processes including cell cycle, cell proliferation and cell 
differentiation, including adipocyte differentiation (Bost et al., 2005). The nature of 
this increased phosphorylation (or dephosphorylation failure), and thus relative 
increased activity, of ERK is not clear. 
Moreover, the decreased lipid accumulation and adipocyte size in the HFD-fed KO 
mice were postulated to arise from attenuated modulation of SNARE assembly. In 
adipocytes, lipid droplet formation and growth occurs through fusion of neutral TAG 
packaged-amphipathic lipoproteins with the phospholipid monolayer surrounding the 
lipid droplet. This fusion is believed to be mediated by the adipocyte vSNARE protein 
VAMP-4 and the tSNARE proteins syntaxin-5 and SNAP-23 (Bostrom et al., 2007). 
Analysis of epididymal WAT showed that the amount of co-immunoprecipitated 
VAMP-4 and syntaxin-5 in the HFD-fed KO mice was significantly less (by ~35%) 
than that in the HFD-fed Wt mice. This suggested that in adipocytes -synuclein 
modulates SNARE complex-mediated fusion between the amphipathic lipoprotein-
packaged neutral TAG and the phospholipid monolayer surrounding the lipid droplet, 
thus contributing towards lipid accumulation in WAT. 
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1.4. The role of -synuclein in mammary gland tumourigenesis  
-synuclein was named breast cancer-specific gene1 (BCSG1) because it was found 
to be aberrantly expressed in a large percentage of advanced infiltrating breast 
carcinomas, compared to normal tissue and benign tumours where its levels were 
absent or hardly detectable (Ji et al., 1997). Investigations of -synuclein, whose 
physiological function is not clearly known yet, have since revealed some properties 
that support its role in breast cancer: it was found to stimulate the growth and 
proliferation of cancer cells, promote the survival of cancer cells and inhibit 
apoptosis, inhibit the mitotic check point function and thereby increase chromosomal 
instability, and enhance breast cancer cell motility and metastasis. These findings 
were largely based on cell culture system studies utilizing breast cancer cell lines 
and raise questions about the in vivo role of -synuclein in the development and 
progression of breast cancer. The studies that led to these findings are discussed 
below.  
1.4.1. Aberrant expression of -synuclein in tumours of different tissues occurs 
in a stage-specific manner 
To identify genes differentially expressed in breast cancer tissue compared to normal 
tissue, a high-throughput differential cDNA sequencing approach was utilized. A 
gene that was expressed abundantly in a breast cancer cDNA library but scarcely in 
a normal breast cDNA library was isolated and named BCSG1 (Ji et al., 1997). 
Furthermore, in situ hybridization analysis found BCSG1 to be expressed in a tumour 
stage-specific manner: it was undetected in normal or benign lesions, partially 
expressed in ductal carcinoma in situ and abundantly expressed in advanced 
infiltrating carcinoma. This raised the possibility of using it as a marker of breast 
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cancer progression. No tumour-specific mutations were found when sequence 
information from breast tumour and normal mRNA and gene were compared, 
suggesting that the development of breast tumour correlates with overexpression of 
the wild type gene (Ninkina et al., 1998). 
In addition to breast carcinomas, the aberrant expression of -synuclein was also 
confirmed in preneoplastic lesions of the ovary and in a high percentage of ovarian 
carcinomas where it was also mostly restricted to late stages III and IV. Consistent 
with previous findings, when the tumours were analysed for gene mutations neither 
DNA abnormalities like rearrangements and amplifications nor sequence changes 
were detected (Bruening et al., 2000). This, again, suggested that the aberrant 
expression was mediated at the transcriptional or post-transcriptional levels. 
Moreover, the abnormal expression of -synuclein was also detected in a high 
percentage (67.5%) of tumours covering a wide range of cancer types, including 
liver, gastric, lung, colon, oesophagus, prostate, cervical and breast, but rarely in 
normal adjacent tissue (0.6%). This expression was also stage-specific where little 
expression was detected in the early stage I and abundant expression was detected 
in the later stages II-IV (Liu et al., 2005). Another important finding was the strong 
correlation between the aberrant expression in the primary tumours and the 
progression to distant metastases in patients irrespective of the cancer type. Further 
studies, particularly in breast cancer (Guo et al., 2007; Wu et al., 2007; Wu et al., 
2003), and in liver cancer (Zhao et al., 2006), confirmed the above findings of late 
stage-specific aberrant expression of -synuclein in tumours and its correlation to 
metastasis. The above studies lend support to the potential use of -synuclein as a 
marker of cancer progression and as a possible target for cancer treatment. 
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1.4.2. Mechanisms of -synuclein gene aberrant expression 
The loss of epigenetic control of -synuclein expression through CpG island 
demethylation was first revealed in a study utilizing human cancer cell lines (Lu et 
al., 2001). The CpG island of exon 1 of -synuclein-positive SKBR-3 and T47D 
breast cancer cells were found unmethylated, but the CpG island of exon 1 of -
synuclein-negative MCF-7 cells was densely methylated. When the demethylating 
agent 5-Aza-2’-deoxycytidine was added to the MCF-7 cells -synuclein transcription 
was activated. Moreover, the 5’ promoter region was found to be important for the 
basal transcriptional activity of -synuclein gene through a GC-rich sequence 
upstream of the transcription initiation site. This sequence was bound specifically by 
the transcription factor SP1 in cancer cells that were either positive or negative for -
synuclein expression. 
In another study, methylation-specific PCR demonstrated the demethylated status of 
the CpG island of -synuclein gene in all hepatocellular carcinomas examined (Zhao 
et al., 2006). Gupta and co-workers also demonstrated that demethylation of the 
CpG island of exon 1 is a common mechanism employed by both breast and ovarian 
tumour-derived cell lines in the aberrant expression of -synuclein gene (Gupta et al., 
2003a). Also, cigarette smoke extract induced demethylation of -synuclein CpG 
island in the -synuclein-negative A549 lung cancer cells, leading to the expression 
of the gene. This was shown to be due to an effect of down-regulating DNA methyl 
transferase3B (DNMT3B) that keeps -synuclein CpG island in a methylated state to 
silence its expression. Cigarette smoke extract also stimulated in vitro cell invasion 
of these cells in a -synuclein-dependent manner, as the number of invading cells 
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decreased to the control levels when siRNA was used to knockdown -synuclein (Liu 
et al., 2007a). 
The aberrant expression of -synuclein may be further aggravated by the presence 
of high levels of the transcription factor activator protein 1 (AP1) in cancer cells. 
Intron 1 of -synuclein gene was shown to contain two AP1 binding sites, the 
mutation of which resulted in the marked down-regulation of -synuclein expression 
and subsequent suppression of tumour phenotype (Lu et al., 2002). It was also 
shown that c-Jun, the major component of AP1, bound the two AP1 sites and that 
transfecting a dominant negative mutant of c-Jun into T47D breast cancer cell line 
significantly reduced transcription of -synuclein. This investigation also 
demonstrated a significant inhibition of anchorage-independent growth of T47D cells 
expressing either the dominant negative mutant of c-Jun or -synuclein antisense 
mRNA. It is thus feasible that in the aberrant expression demethylation of the CpG 
island occurs first (to allow the basal transcription to proceed) followed by increased 
expression of -synuclein through elevated levels of AP1 in cancer cells. Indeed, 
many signalling pathways including c-Jun N-terminal kinase (JNK), protein kinase C 
(PKC) and MAPK/ERK were shown to converge on AP1 sites (Grundker et al., 2001; 
Song et al., 2001). The role of -synuclein in the proliferation and growth, survival 
and resistance to apoptosis, and in invasion and metastasis of cancer cells was 
shown in several studies using mostly cell culture systems, but also using in vivo 
systems. 
1.4.3. -synuclein in breast cancer cell growth and proliferation 
To investigate the role of -synuclein in cancer cell proliferation, -synuclein cDNA 
was stably transfected into -synuclein-negative MCF-7 breast cancer cells. This 
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expression resulted in a significant increase in the growth of these cells under both 
anchorage-dependent and anchorage–independent conditions, suggesting a role for 
-synuclein in cell growth and proliferation (Liu et al., 2000). Also, and as already 
mentioned above, knocking down of -synuclein using antisense mRNA in the -
synuclein-positive T47D breast cancer cell line produced a significant inhibition of 
anchorage-independent growth of the cells (Lu et al., 2002). These findings were 
confirmed by a recent study utilizing short hairpin RNA (shRNA) to knockdown -
synuclein in -synuclein-transfected MCF-7 cells and xenografting them in nude mice 
(Shen et al., 2011). The -synuclein-knockdown xenografts yielded significantly 
smaller tumour masses than the control ones, suggesting a role for -synuclein in 
tumour growth and a possible use as a therapeutic target. 
To find a role for -synuclein in steroid-responsive mammary tumourigenesis, the 
effect of -synuclein on the transcriptional activity of estrogen receptor-alpha (ER-) 
was investigated (Jiang et al., 2003). Estradiol (E2)-stimulated ER- transcriptional 
activity was significantly increased when MCF-7 cancer cells overexpressing -
synuclein were treated with estrogen, compared to estrogen-treated, -synuclein-
negative MCF-7 cells. This effect of -synuclein was ligand-dependent as -synuclein 
had no effect in the absence of E2. Moreover, it was shown that overexpression of -
synuclein stimulated ligand-dependent cell proliferation whereas suppression of 
endogenous -synuclein expression by antisense -synuclein mRNA-expressing 
plasmid constructs significantly inhibited it. Treatment with antiestrogens inhibited 
this ligand-dependent effect. Taken together, these results suggest that -synuclein 
is required for efficient ER- signalling. 
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Building on this study, the same group showed that -synuclein was a component of 
the heat shock protein (Hsp)-ER- complex, and that it enhanced the affinity of ER- 
to estrogen as it activated the ligand-dependent ER- transcriptional activity (Jiang 
et al., 2004). It is noteworthy to emphasise here once again that all three members of 
the synuclein family have been shown to possess chaperone-like activity: they 
suppressed the aggregation of thermally denatured alcohol dehydrogenase and 
chemically denatured insulin (Souza et al., 2000). Taken together, these data 
support a role for -synuclein in hormone-responsive mammary gland 
tumourigenesis. 
Contrary to the above findings of enhancing breast cancer cell growth by aberrant 
expression of -synuclein, growth of human esophageal squamous cell carcinoma 
(ESCC) was negatively affected by upregulation of -synuclein (Zhou et al., 2003). In 
this investigation, semiquantitative RT-PCR on 27 pairs of ESCC samples and 
corresponding normal tissue was performed to assess the expression pattern of -
synuclein. All normal samples were found to express -synuclein. However, -
synuclein was downregulated in approximately 60% (16/27) of the ESCC samples 
while it was upregulated in only 22% (6/27) of the samples and was not changed in 5 
samples. In a functional assay, -synuclein was ectopically overexpressed in ESCC 
9706 cell line. This retarded the growth rate in either low or high serum medium and 
inhibited the transformation ability of the cells growing in soft agar. These findings 
led to the conclusion that -synuclein may act as a negative regulator in human 
ESCC development. 
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1.4.4. -synuclein may promote survival and inhibit apoptosis of cancer cells 
One of the properties that tumours acquire in their defiance of the normal cell 
physiology is the ability to promote survival and inhibit apoptosis. A role for -
synuclein in promoting this property was revealed in a cell culture study utilizing 
ovarian cancer cell lines ectopically overexpressing -synuclein (Pan et al., 2002). In 
these cells, co-immunoprecipitation of -synuclein and two major mitogen-activated 
protein kinases (MAPKs), extracellular-regulated protein kinases (ERK1/2) and c-Jun 
N-terminal kinase 1 (JNK1), was shown, thus demonstrating the ability of this protein 
to associate with kinases involved in cell proliferation and apoptosis. Overexpression 
of -synuclein induced activation of the survival factor ERK1/2 and attenuated 
activation of the pro-apoptotic factor JNK1 when the cells were subjected to heat 
shock, arsenate or UV radiation stress. In addition, the -synuclein overexpressing 
cells exhibited resistance to the chemotherapeutic drugs vinblastine and paclitaxel. 
However, when cells were treated with the mitogen-activated protein kinase kinase 
(MEK1/2) U0126 inhibitor, ERK1/2 activation was suppressed and resistance to 
paclitaxel was partially overcome. Also, -synuclein overexpression significantly 
down-regulated JNK1 and its downstream caspase-3 activity in response to 
vinblastine or paclitaxel application, suggesting that -synuclein blocks the JNK1-
regulated apoptotic response induced by these chemotherapeutics. Taken together, 
these results support a role for -synuclein in promoting survival of cancer cells 
through activation of ERK1/2 and inhibiting apoptosis through downregulation of 
JNK1 activity (Pan et al., 2002). 
-synuclein was also found to associate with the mitotic checkpoint kinase BubR1 in 
breast cancer cells (Gupta et al., 2003b). This association resulted in the reduction of 
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BubR1 protein levels without affecting its mRNA levels. This was evidenced by 
blocking of this effect through treatment of -synuclein transfected cells with the 
selective 26S proteasome inhibitor MG-132, suggesting the involvement of the 
proteasome machinery in -synuclein-mediated reduction of BubR1 levels. Inaba and 
colleagues treated -synuclein-positive breast cancer cells with the microtubule-
destabilizing drug nocodazole and reported a 3-fold reduction in mitotic index (Inaba 
et al., 2005). This treatment also resulted in multinucleation in over one third of the 
cells compared to only 10% in the -synuclein-negative cancer cells. Moreover, 
apoptosis was induced in about 30% of the -synuclein-negative cells, whereas only 
10% of the -synuclein-positive cells became apoptotic. Furthermore, nocodazole 
treatment of -synuclein-expressing breast cancer cells suppressed the activity of 
caspase 3. These effects were relieved by overexpressing BubR1. Taken together, 
these results suggest that -synuclein overexpression compromises the mitotic 
checkpoint control by interfering with the function of BubR1. This contributes to 
chromosomal instability of cancer cells and subsequently may accelerate the 
progression of cancer and speed up tumour metastasis, and may contribute to the 
resistance to anti-microtubule drug-induced apoptosis. 
1.4.5. -synuclein and metastasis 
The role of -synuclein overexpression in invasion and metastasis of breast cancer 
cells was first shown in a study using -synuclein-negative MDA-MB-435 cells (Jia et 
al., 1999). The cells were transfected with -synuclein and their properties were 
studied in cell culture as well as in vivo. In cell culture, -synuclein overexpression 
significantly stimulated the migration and invasion of the cells at least 3-fold and 4-
fold, respectively, compared to -synuclein-negative cells. For in vivo studies, the 
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transfected and control cells were implanted in the mammary fat pads of athymic 
nude mice. Mice developed tumours with no difference in incidence. Axillary lymph 
nodes and lungs were examined at autopsy 40 days post implantation for general 
morphology and microscopically on H&E-stained sections. -synuclein-positive cells 
showed significantly higher average lymph node positivity (about 70%) than -
synuclein-negative cells (27%). Lung metastases were also significantly higher in -
synuclein-positive cells. These results emphasize the correlation between the 
abundant levels of -synuclein in primary tumours and the progression to metastasis. 
The effect of -synuclein overexpression on cell motility was further demonstrated in 
breast and ovarian cancer cell lines (Pan et al., 2006). In the ovarian cancer line 
OVCAR5 that expresses high levels of -synuclein, in vitro cell motility was 
significantly decreased when -synuclein was knocked down using siRNA compared 
to untreated or mock-treated cells. The levels of the active forms of GTPases Ras-
related C3 botulinum toxin substrate (RAC) and cell division control protein 42 
(CDC42) were also increased in OVCAR5 cells by overexpressing -synuclein. In 
addition, -synuclein overexpression increased the levels of activated RHO GTPase 
2-3 fold in MDA-435 breast cancer line. Also, ERK increased cell motility and was 
associated with and activated by -synuclein in A2780 and OVCAR5 ovarian cancer 
lines overexpressing -synuclein. The involvement of ERK and RHO pathways in -
synuclein–enhanced cell motility was further evidenced by a significant reduction in 
cell motility when the cells were treated with known inhibitors of GTPase (C. difficile 
Toxin B) and ERK (MEK1 inhibitor UO126). These data suggest a role for -
synuclein in breast and ovarian cancer metastasis by enhancing cell motility through 
activation of the RHO family GTPases and ERK. 
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1.4.6. -synuclein transgenic mammary glands exhibit increased epithelial 
proliferation  
Further support to the role of -synuclein in mammary gland tumourigenesis came 
from a study using transgenic mice overexpressing -synuclein under the control of 
mouse mammary tumour virus (MMTV) promoter (Liu et al., 2007b). Whole mount 
histological analysis showed that the transgenic mammary gland exhibited a 
significant increase in the ductal branching morphology and terminal end bud density 
starting at 10 weeks of age. This indicates a highly proliferative capacity of epithelial 
cells at the terminal end buds. This pregnancy-like phenotype was confirmed by 
H&E-stained sections which also revealed hyperplasia-like structures in the 
transgenic mammary glands characterized by areas of multilayered epithelium. A 
one year-follow up revealed no development of carcinoma. 
To determine whether -synuclein-enhanced ER- signalling was responsible for this 
phenotype, ER-mediated transcriptional activities of the E2-regulated Trefoil factor 1 
(TFF1/PS2) and Cathepsin D (Cat-D) genes were measured. Compared to control 
mice, the levels of PS2 and Cat-D in the transgenic mammary glands were 3.4-fold 
and 4.8-fold higher, respectively. No significant difference in ER- levels was 
observed between the control and transgenic mice, indicating that the upregulation 
of PS2 and Cat-D was not due to ER- levels but due to increased ER- signalling. 
This conclusion was further supported by the fact that inhibiting ER- signalling, 
through the use of tamoxifen (an estrogen antagonist) and ovarectomized mice, 
blocked -synuclein-induced proliferation. These -synuclein-induced ER- effects 
are likely to be mediated by the chaperone activity of -synuclein as it participates in 
the Hsp-based ER--multiprotein chaperone complex. 
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1.4.7. -synuclein as a potential biomarker for breast cancer progression and 
therapeutic target 
To determine whether -synuclein may be used as a biomarker of breast cancer 
prognosis and progression, 438 clinical breast specimens, of which 358 were 
cancerous, were screened for -synuclein expression by immunohistochemistry (Guo 
et al., 2007). The expression was strongly correlated with the stage of breast cancer, 
tumour size, lymph node involvement, metastasis and Her-2 (ErbB2) status, but not 
with estrogen receptor and progesterone receptor expression status. After a 64-
month follow up patients whose tumours expressed -synuclein had a significantly 
shorter disease-free survival (DFS) and overall survival (OS) and a high probability 
of death compared to those with -synuclein-negative tumours. Multivariate analysis 
concluded -synuclein to be a strong independent prognostic variable. This can be 
very helpful when taking decisions of breast mastectomy. 
-synuclein may also be a potential target for treatment. In fact, an ANK peptide was 
designed and shown by co-immunoprecipitation and colocalization techniques to 
associate with -synuclein (Singh et al., 2007). When this peptide was microinjected 
into -synuclein-positive MCF-7 cells a nocodazole-induced cell killing response 
similar to that of -synuclein-negative cells was produced. Moreover, overexpression 
of eGFP-ANK fusion protein resulted in about 3.5-fold reduction in -synuclein-
induced resistance to paclitaxel. This effect of ANK peptide is thought to be through 
its association with -synuclein, thus allowing BubR1 to function in the mitotic 
checkpoint control and trigger apoptosis. Additional support to this finding can be 
found in a previous investigation by Zhou and co-workers (Zhou et al., 2006). They 
showed a significant correlation between -synuclein positivity and resistance to the 
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antimicrotubule drug paclitaxel in 12 breast cancer cell lines. They further 
demonstrated that downregulating -synuclein expression in these cells sensitized 
them to paclitaxel-induced cytotoxicity. 
The highlighted above studies indicate that -synuclein plays a role in the 
tumourigenesis of the mammary gland. It stimulates the growth and proliferation of 
cancer cells, promotes the survival of cancer cells and inhibits apoptosis, inhibits the 
mitotic check point function and thereby increases chromosomal instability, and 
enhances breast cancer cell motility and metastasis. The above effects were 
obtained as a consequence of aberrant expression/overexpression of -synuclein 
largely in cell culture systems utilizing breast cancer cell lines. In transgenic mice, its 
aberrant expression seemed to stimulate ligand-dependent ER- signalling, leading 
to a highly proliferative pregnancy-like phenotype of mammary epithelial cells and 
branching morphology. Therefore, if -synuclein had an influential role in enhancing 
the progression, and perhaps contributing to the development of mammary gland 
tumourigenesis, then abrogation of its expression would be expected to prevent the 
formation or retard the progression of mammary tumours. If such a result was 
achieved, more serious efforts would be directed towards exploring the use of -
synuclein as a biomarker of breast cancer progression and prognosis, and certainly 
as a target for treatment. However, the role of endogenous -synuclein in mammary 
gland tumourigenesis has not been studied in an appropriate in vivo model and our 
research programme is the first attempt to demonstrate directly whether -synuclein 
is required for the development and/or progression of ErbB2-induced mammary 
tumours. 
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1.5 Aims 
The main goal of this research project was to study the possible role of endogenous 
-synuclein in mammary gland tumourigenesis in an appropriate in vivo system. For 
this purpose, a breast cancer transgenic, ErbB2 mutant mouse model was chosen 
from which -synuclein gene was later deleted. This mutant ErbB2 model was 
chosen due to a previous observation in our lab correlating the expression of ErbB2 
with that of -synuclein in the murine mammary tumour cell line MG1361 , a cell line 
that was originally established from a mammary adenocarcinoma isolated from the 
chosen model. To assess the effect of -synuclein gene ablation on ErbB2-induced 
mammary gland tumourigenesis the following objectives were set: 
1. To investigate expression of -synuclein in normal mammary gland tissue and 
mammary tumours in mouse cancer models. 
2. To study expression of -synuclein in mouse and human cancer cell lines and 
the subcellular localization of expression in the MG1361 mouse mammary 
tumour cell line. 
3. To reveal the effect of -synuclein gene ablation on the normal development 
of the mouse mammary gland. 
4. To investigate the effect of -synuclein gene ablation on mammary gland 
tumourigenesis in the constitutively activated ErbB2 transgenic model. 
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Chapter 2. Materials and Methods 
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2.1. Mouse lines used 
2.1.1. Generation of experimental and control cohorts 
Figure 2.1 below shows a diagram summarizing the breeding scheme used to 
produce the control and experimental groups. 
 
C57BL6 +/- X  FVB +/+
FVB +/-
Intercross
Backcross to FVB +/+
For 6 generations
FVB NK Hemizygous X  FVB -/- +             
NK Hemizygous +/-
Intercross
Wt    +/- X  NK Homozygous    +/-
NK Hemizygous -/- + NK Hemizygous +/+ (experimental groups)  
FVB +/+ (control groups)
Stage 1
Stage 2
 
Figure 2.1. Breeding scheme. Stage I produces the control groups: FVB -/- and FVB 
+/+. Stage II yields the experimental groups carrying the constitutively activated NK 
transgene in a Hemizygous form: one group homozygous for the -synuclein KO 
allele (NK Hemizygous / -/-) while the other homozygous for the -synuclein Wt allele 
(NK Hemizygous / +/+). 
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The experimental cohorts used in the main in vivo experiment were generated by 
breeding FVB -synuclein KO line with a breast cancer model harbouring a 
constitutively activated ErbB2 transgene under the control of MMTV promoter (NK 
line). The -synuclein KO line was generated in the laboratory of Prof. Vladimir 
Buchman as described previously by Ninkina and co-workers (Ninkina et al., 2003), 
while the establishment of the NK mutant line was described earlier by Muller and 
co-workers (Muller et al., 1988). The pregnancy passage control and experimental 
females were mated at about 7 weeks of age and pups weaned at 18-20 days of 
age. 
2.1.2. Husbandry information 
All work on animals was carried out in accordance with the United Kingdom Animals 
(Scientific Procedures) Act (1986) and European Directive EC 86/609. The animals 
were bred and maintained in cages with unlimited supply of food (Rodent pellets 
from Special Diets Services) and drinking water, with beddings changed 1-2 times 
per week. A light cycle of 12 hrs light:12 hrs darkness was used. 
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2.2. Genotyping 
2.2.1. Standard PCR technique. 
This was used to genotype the -synuclein Wt and KO alleles throughout the 
breeding process, as well as the NK transgene in the experimental groups. Genomic 
DNA (gDNA) was extracted using a phenol-based method as outlined below. 
Phenol-based gDNA Extraction 
Ear/tail biopsy of about 20-50 mg was obtained from the animal into a 1.5 ml 
eppendorf tube and stored at -20o C until DNA extraction. 300 µl of *DNA extraction 
buffer solution was added and the tube incubated in a water bath at 55o C for a 
minimum of 4 hours or overnight. After pulse vortexing, 300 µl of basic phenol (pH 
8.0) (Sigma) was added and the tube vortexed and centrifuged for 10 minutes at 
13000 rpm. The supernatant was transferred to a new tube for another round of 
phenol extraction and the supernatant transferred to a new eppendorf tube. An equal 
volume mixture of phenol/chloroform (Fisher Chemical) was added and same 
centrifugation repeated. The supernatant was transferred to a new tube and 10 µl of 
3M NaOAc (sodium acetate, Sigma) plus 600 µl of absolute analytical grade ethanol 
(Fisher Chemical) was added. The tube was inverted few times for mixing, 
centrifuged for 2 minutes at maximum speed and the supernatant was discarded. 
The formed pellet was washed 3 times with 70% cold ethanol, speed-vacuum dried 
at 37o C for 5-10 minutes and resuspended in 50 µl of nuclease-free, double distilled 
water. 
*DNA extraction buffer 
1 % SDS (Sodium Dodecyl Sulfate) (Sigma-Aldrich) 
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100 mM NaCl (Sigma-Aldrich) 
50 mM Tris pH 8.0 (Hydroxymethylaminoethane) (Sigma-Aldrich) 
2 mM EDTA (Ethylenediaminetetraacetic acid) (Sigma-Aldrich)  
2 mg/ml Proteinase K (Sigma-Aldrich), added fresh. 
PCR protocol 
5 µl of DNA suspension was added to a thin-walled PCR reaction tube and 45 µl of 
the following PCR Mastermix (prepared for 10 samples) was added: 
PCR-grade water 440 µl 
10x PCR Reaction Buffer (Fermentas) 50 µl 
dNTPs (25 mM) (Fermentas) 4 µl 
*Primers (100 µM (Sigma): forward 2.5 µl 
                                  Reverse 2.5 µl  
Taq DNA Polymerase (5 U/µl) (Fermentas) 2.5 µl  
The samples were then placed in a thermal cycler machine (PCR Express from 
Hybaid) and subjected to the following program: 
2 mins Initial denaturation 94 oC 
Then 45 cycles of 15 sec Denaturation 94 oC 
           30 sec Primer annealing 60 oC 
           40 sec Template extension 72 oC 
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The samples were then loaded and electrophoresed on a *2.5% agarose gel to 
separate the amplified fragments for genotype identification/confirmation. The bands 
were visualized and photodocumented using Gel Doc 2000 Transilluminator and 
Quantity One 4.2.1 software (Bio-Rad). 
*2.5% agarose gel 
*TAE Buffer 100 ml 
Agarose powder (Eurogentec) 2.5 g 
Ethidium bromide (10 mg/ml) (Sigma) 5.0 µl 
*TAE electrophoresis buffer (50x stock solution) 
Tris-base (Sigma) 242 g 
0.5 M EDTA (pH 8.0) (Sigma) 100 ml 
Glacial acetic acid (Fisher Scientific) 57.1 ml 
Deionized water adjust to 1 litre 
*Primer sequences used for standard PCR genotyping 
For -synuclein genotyping three primers, with a common upstream primer for both 
Wt and KO alleles and a specific downstream primer for each, were used to 
potentially produce two amplified fragments: a wild-type fragment of 480 bp and a 
knock-out one of 397 bp: 
Common upstream 5ʼ-AGTCCTGGCACCTCTAAGCA-3ʼ 
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Wild type downstream 5ʼ-GGGCTGATGTGTGGCTATCT-3ʼ 
Knock-out downstream 5ʼ-GAAGAACGAGATCAGCAGCC-3ʼ 
For NK transgene genotyping, a forward and a reverse primer produced a 622 bp 
fragment: 
Forward 5ʼ-TTTCCTGCAGCAGCCTAC-3ʼ 
Reverse 5ʼ-CGGAACCCACATCAGGCC-3ʼ 
2.2.2. Quantitative real-time PCR (q-PCR) 
This was used for genotyping the NK homozygous male parent used to produce the 
experimental NK hemizygous female cohorts, as it was necessary to differentiate 
between the homozygous and hemizygous genotypes. The technique was also 
used, with a preceding reverse transcription reaction step (qRT-PCR), to assess the 
level of mRNA expression in some mouse mammary cancer cell lines, as will be 
indicated later. For the purpose of genotyping, genomic DNA was purified from ear 
biopsies using a commercial kit (Promega Wizard SV Genomic DNA purification kit) 
in accordance with the manufacturer’s protocol. The real-time qPCR reaction was 
performed in an Applied Biosystems StepOne Real-Time PCR System (Applied 
Biosystems). Two *mastermixes were prepared, one included specific forward and 
reverse *primers to amplify a 69 bp fragment from the NK transgene, while the other 
utilized specific *primers for the housekeeping gene GAPDH for use as an internal 
control. The passive reference dye ROX (Finnzymes) was used to calibrate the 
thermal cycler machine for background fluorescence (non-PCR related fluorescence 
signal variation). 
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*Mastermix solution (sufficient for 24 wells/reactions) 
PCR grade water 376 μl 
10x TrueStartTM PCR buffer (Fermentas) 58 µl 
25 mM MgCl2 (Fermentas) 58 µl 
dNTPs (25 mM) (Fermentas) 6 µl 
CYBR Green (100 x) (Finnzymes) 6 µl 
Rox (50x) (Finnzymes) 6 µl 
Primers (100 µM) (Sigma): forward 3 µl 
                                          reverse 3 µl 
TrueStartTM HotstartTaq Polymerase (5U/µl) (Fermentas) 4 µl 
*Primers to amplify a 69 bp fragment from the NK transgene 
Forward 5ʼ-CCCCGGGAGTATGTGAGTGA-3ʼ 
Reverse 5ʼ-TGAGCTGTTTTGAGGCTGACA-3ʼ 
*Primers for -synuclein expression 
Forward 5ʼ-CCATGGACGTCTTCAAGAAAGG-3ʼ 
Reverse 5ʼ-CGTTCTCCTTGGTTTTGGTG-3ʼ 
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*Primers for the housekeeping gene GAPDH 
Forward 5ʼ-CACTGAGCATCTCCCTCACA-3ʼ 
Reverse 5ʼ-GTGGGTGCAGCGAACTTTAT-3ʼ 
18 µl of the relevant mastermix was added to a well containing 2 µl of gDNA 
template. Each sample was run in triplicates to ensure accuracy. The 48 well plate 
was then spun for a minute at 1200 rpm/min and loaded onto the StepOne real-time 
thermocycler. The samples underwent the following program: 
10 mins  Hot start/Initial denaturation 94 oC 
Then 40 cycles of 15 sec Denaturation 94 oC 
   60 sec Primer annealing and extension 60 oC 
A step-wise melting curve at increments of 0.3 oC was performed at the end of the 
thermocycling to determine the melting point of the amplicon and ensure specificity. 
StepOne Software v 2.0 (Applied Biosystems) was used to run and analyse the 
products. Fold change was calculated using the 2-ΔΔCt comparative method. 
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2.3. Tumour monitoring 
The mammary glands of the control and experimental female groups were monitored 
for tumour development. This was done by regular palpation (once or twice a week) 
of the mammary glands and recording the time and size of any tumours detected. 
Tumour size/volume was measured manually using an external calliper (Camlab) to 
determine width (greatest transverse diameter) and length (greatest longitudinal 
diameter) linear dimensions. Tumour size was calculated by use of the modified 
ellipsoid formula: 
Tumour volume = ½ x Length × Width2. 
The following parameters were recorded and tabulated: age of animal (days) at 
parity, age at tumour detection, number of palpable tumours/animal, age at sacrifice, 
days from parity to sacrifice, days from tumour detection to sacrifice, age tumours 
reached a size of ~250 mm3. To assess tumour kinetics, days for tumours to 
progress from a size of 250 mm3 to a size of 750 mm3 and 1500 mm3 was noted. 
Eventually, the animals were sacrificed when the length of a tumour reached 20 mm, 
as required by the Home Office regulations. Animal sacrifice was carried out by 
cervical displacement in a designated procedure room in the animal house. At 
sacrifice, formed tumours and normal mammary gland tissue were harvested. Each 
harvested tissue was divided into 2 halves, one placed directly into liquid Nitrogen for 
subsequent storage at -80 oC while the other half was placed into a 20 ml tube 
containing fresh 4% formaldehyde fixative solution for histological sectioning. 
Furthermore, metastasis was investigated by post-mortem visual inspection and 
histological analysis of lung and kidney tissues. 
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2.4. Mammary gland whole mounts 
Upon sacrificing the animal, either of the fourth pair of mammary glands (L4 or R4) 
was dissected out and spread on a microscope slide taking care to preserve the shape 
and structure of the gland. The gland was then fixed in *Carnoy's solution for about 3 
hours and transferred to 70% ethanol for 15 minutes. It was then washed with 
running tap water for about a minute and transferred to *Carmine solution for 
overnight staining in the dark at room temperature. The gland was later washed with 
tap water until the water ran clear. It was then dehydrated in a series of increasing 
alcohol concentration (50%, 70%, 90% and 100%) for 10 minutes/step and then 
immersed in xylene overnight for defatting the gland tissue to obtain clear ductal 
morphology. The gland was then mounted in DPX for visualization under a 
dissecting microscope and photodocumented. 
*Carnoy's solution 
60% ethanol, 30% chloroform and 10% acetic acid. 
*Carmine Alum staining solution 
To 500 ml distilled water, 1 g of carmine And 2.5 g of aluminum potassium sulfate 
were added and mixed well. The solution was then boiled for 20 minutes and the 
final volume was adjusted to 500 ml with distilled water. The solution was filter 
sterilized and a crystal of thymol was added as a preservative. The staining solution 
was stored at 4°C. 
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2.5. Conventional histology 
(All reagents were purchased from Fisher Scientific unless otherwise stated). 
2.5.1. Fixation  
Harvested tissue samples were immediately fixed in a freshly prepared *4% 
formaldehyde (Sigma-Aldrich) solution overnight at 4 C and then transferred to 70% 
alcohol before processing. 
*4% formaldehyde solution in PBS 
For preparation of a 100 ml volume, 4 g of paraformaldehyde powder (Sigma) was 
weighed in a fume cupboard and transferred into a bottle containing about 80 ml of 
ddH20 already placed on a hotplate magnetic stirrer (about 60
oC).The bottle was 
heated up for few minutes and about 100 µl of 10 N NaOH was added to adjust the 
pH to between 7 and 8 for paraformaldehyde to dissolve and form a clear solution of 
formaldehyde. The solution was allowed to cool and then filtered through a filter 
paper. 10 ml of *10x PBS was added and the volume adjusted to 100 ml. The pH 
was rechecked and, if necessary, adjusted to 7.2-7.8.  
*10x PBS solution  
This was prepared by dissolving PBS tablets (Sigma-Aldrich) in the appropriate 
volume of ddH20 according to the manufacturer’s instructions. 
2.5.2. Histological sectioning 
The samples were embedded with paraffin wax at 60C by a Leica TP1050 fully 
enclosed automatic tissue processor (Leica) using the following schedule: 
70% alcohol 1:00 hr 
87 
 
90% alcohol 1:30 hr 
100% alcohol 1:30 hr 
100% alcohol 2:00 hr (x2) 
Xylene 1:00 hr (x2) 
Paraffin wax 1:30 hr 
Paraffin wax 2:00 hr (under vacuum) (x2) 
 
After processing, samples were embedded in paraffin wax blocks using a Leica 
EG1150H Embedding Centre. The paraffin wax was then allowed to harden rapidly 
by placing the blocks on a Leica EG1140C cold plate. 5μm-thick sections were then 
cut using a Leica RM2235 rotary microtome, floated on warm water and mounted on 
Polysine microscope slides. The sections were allowed to dry overnight at 45 oC. 
2.5.3. Hematoxylin and Eosin (H&E) staining 
Slides were stained for H&E using an R.A. Lamb Histomate staining machine (R.A. 
Lamb) programmed to carry out the following protocol: 
Xylene 2 Mins (x3) 
100% Alcohol 2 Mins (x3) 
95% Alcohol 1 Mins 
70% Alcohol 1 Mins 
Water 3 Mins 
Gills II Haematoxylin 5 Mins 
Water 3 Mins 
1% Acid Alcohol 10 Secs 
Water 5 Mins 
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1% Eosin 5 Mins 
Water 30 Secs 
70% Alcohol 30 Secs 
95% Alcohol 1 Mins 
100% Alcohol 1 Mins 
100% Alcohol 2 Mins (x2) 
Xylene 1 Mins 
Xylene 2 Mins (x2) 
 
DPX mountant (BDH) was then used to mount the sections under a cover glass 
(VWR international).  
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2.6. Immunohistochemistry (IHC) 
Normal and tumour mammary gland samples were fixed in either 4% formaldehyde 
overnight at 4 C or in Carnoy’s solution for 4 hours at room temperature. 5 m-thick 
sections were then obtained onto microscope slides as outlined above in the 
conventional histology section. Immunostaining for mouse -synuclein in the 
mammary tissue sections utilized an affinity-purified polyclonal antibody (SK23), 
which was produced in the laboratory of Prof. Vladimir Buchman (Buchman et al., 
1998b). The sections were first deparaffinized by rocking in xylene for 5 minutes and 
then rehydrated using a decreasing concentration of alcohol solution as follows: 
100% Ethanol Rock for 5 Mins 
95% Ethanol Rock for 5 Mins 
50% Ethanol Rock for 5 Mins 
ddH20 Rock for 5 Mins (x2) 
 
The sections were quenched for endogenous peroxidase activity in a solution of 3% 
H2O2 (Sigma) in Methanol (Fisher Scientific) for 20 minutes and then washed 3 times 
with ddH20 for 5 minutes each time. They were next blocked for 90 minutes in *10% 
horse serum (Invitrogen) made in T-PBS solution (1x PBS containing 0.4% Triton X-
100). This was followed by an overnight incubation at 4 C in a 1:500 dilution of 
rabbit polyclonal SK23 anti-mouse -synuclein (primary antibody) in blocking 
solution. The sections were washed in 1x PBS 3 times of 5 minutes each and 
subsequently incubated in a 1:500 dilution of secondary antibody (biotinylated goat 
anti-rabbit IgG) (Vector Laboratories) in T-PBS solution. Vectastain containing 
Avidin-Biotin-Horseradish Peroxidase enzyme Complex (ABC complex) (Vector 
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Laboratories) was later added according to the manufacturer’s protocol. The 
samples were then washed with 1x PBS. Immunoreactivity was detected by addition 
of the horseradish peroxidase (HRP) substrate Diaminobenzidine (DAB) (Sigma) 
until visualization of the characteristic brown colour product was possible (about 5 
minutes). The samples were instantly washed with 1x PBS to prevent excess 
colouration. They were next washed 3 times in ddH2O and dehydrated by passing 
through a series of increasing alcohol concentration as follows: 
50% Ethanol Rock for 5 Mins 
95% Ethanol Rock for 5 Mins 
100% Ethanol Rock for 5 Mins 
Xylene Rock for 5 Mins 
 
The sections were finally mounted in DPX for visualization under light microscopy. 
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2.7. Cell culture of human and mouse cancer cell lines. 
2.7.1. Mouse cancer cell lines 
Cell line Brief description Culture conditions 
MG 
1361 
(ICLC) 
Transgenic mammary 
gland adenocarcinoma; 
Transformed by Rat 
activated Neu oncogene. 
William’s medium E (Gibco) + 15% FBS 
(Fetal Bovine Serum) (Gibco) + 2 mM L-
Glutamine (Gibco) + 1% non-essential 
amino acids (Sigma-Aldrich) + Penicillin (50 
IU/ml) and Streptomycin (50 µg/ml) (Sigma-
Aldrich). Incubation at 37 C and 5% CO2. 
Cultures split at 1:4. 
4T1 
(ATCC) 
Tumourigenic mammary 
adenocarcinoma 
RPMI-1640 medium (Sigma-Aldrich) + 10% 
FBS + 2 mM L-Glutamine + Penicillin (50 
IU/ml) and Streptomycin (50 µg/ml). 
Incubation at 37 C and 5% CO2. Cultures 
split at 1:4. 
EpH4 Non-tumourigenic 
mammary carcinoma 
Dulbecco’s Modified Eagle Medium (DMEM) 
(Gibco) + 10% FBS + 2 mM L-Glutamine + 
Penicillin (50 IU/ml) and Streptomycin (50 
µg/ml). Incubation at 37 C and 5% CO2. 
Cultures split at 1:4. 
N202-A  Derived from the Rat-Neu 
overexpressing line N202 
which is a mouse 
mammary cancer cell line. 
Dulbecco’s Modified Eagle Medium (DMEM) 
+ 20% FBS + 2 mM L-Glutamine + Penicillin 
(50 IU/ml) and Streptomycin (50 µg/ml). 
Incubation at 37 C and 5% CO2. Cultures 
split at 1:4. 
N202-B Derived from N202-A with 
downregulation of Neu 
expression. 
Dulbecco’s Modified Eagle Medium (DMEM) 
+ 20% FBS + 2 mM L-Glutamine + Penicillin 
(50 IU/ml) and Streptomycin (50 µg/ml). 37 
C and 5% CO2. Cultures split at 1:4. 
Table 2.1. Brief description and culture conditions of mouse cancer cell lines. 
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Table 2.1 above and table 2.2 below show brief descriptions and culture conditions 
of mouse and human cancer cell lines used in this study, respectively. 
2.7.2. Human cancer cell lines 
These included the 9 breast cancer cell lines MDA-MB-468, MDA-MB-231, MCF-7, 
GI101, Hs578T, BT20, BT474, SKBR3 and T47D, and the ovarian cancer cell line 
SKOV3. 
Cell line Brief description Culture conditions 
MCF-7, MDA-
MB-231, 
SKBR3, BT20, 
MDA-MB-468, 
Hs578T 
Mammary 
adenocarcinoma 
Dulbecco’s Modified Eagle Medium (DMEM) + 
10% FBS + 2 mM L-Glutamine, [+ 10 µg/ml 
Bovine Insulin for Hs578T] + Penicillin (50 
IU/ml) and Streptomycin (50 µg/ml). Incubation 
at 37 C and 5% CO2. Cultures split at 1:4. 
(Hs5787 culture split at 1:3; MDA-MB-231 
culture split at 1:6). 
T47D Mammary ductal 
carcinoma 
Dulbecco’s Modified Eagle Medium (DMEM) + 
10% FBS + 2 mM L-Glutamine + Penicillin (50 
IU/ml) and Streptomycin (50 µg/ml). Incubation 
at 37 C and 5% CO2. Cultures split at 1:4. 
SKOV-3 Ovarian 
adenocarcinoma 
Dulbecco’s Modified Eagle Medium (DMEM) + 
10% FBS + 2 mM L-Glutamine + Penicillin (50 
IU/ml and Streptomycin (50 µg/ml). Incubation 
at 37 C and 5% CO2. Cultures split at 1:4. 
BT474 Mammary ductal 
carcinoma 
RPMI-1640 medium + 10% FBS + 2 mM L-
Glutamine + 1mM Na Pyruvate (Sigma-Aldrich) 
+ 0.01 mg/ml Bovine Insulin (Sigma-Aldrich) + 
Penicillin (50 IU/ml and Streptomycin (50 
µg/ml). 37 C and 5% CO2. Cultures split at 1:2. 
Table 2.2. Brief description and culture conditions of human cancer cell lines. 
Standard microbiological procedures and aseptic conditions were followed at all 
stages of handling and growing of cell lines. 
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2.7.3. Defrosting cell stocks 
Cells stored in Cryotubes (Thermoscientific) in liquid N2 were brought up by putting 
tubes directly into dry ice and thawing in water bath at 37 C as soon as possible. 
Under sterile conditions in the laminar flow cabinet, 1 ml of prewarmed (37 C for at 
least 20 minutes) appropriate media was added and the cells transferred to a 15 ml 
falcon tube (Thermoscientific). The cells were centrifuged at 1100 rpm for 5 minutes 
and the supernatant media discarded into 3% Virkon solution (Du Pont). The cells 
were then resuspended in 7 ml of complete media by gentle pipetting up and down, 
transferred to a T25 culture flask (Corning) and incubated at 37 C and 5% CO2 in a 
humidified atmosphere. 
2.7.4. Cell culture 
After defrosting, cells were split as shown in tables above when they reached 80% 
confluency. 1-2 passages were allowed before cells were harvested for protein 
extraction. For passaging, T25 culture flask containing growing cells was placed in 
the laminar flow hood and the media was aspirated and discarded into Virkon 
solution. 1 ml of prewarmed 0.05% Trypsin with EDTA (Invitrogen) was added to 
remove the remaining media, as it might inhibit Trypsin activity, and then aspirated. 
1-2 ml of Trypsin was added onto the monolayer of growing cells and the flask was 
incubated at 37 C and 5% CO2 for 2-5 minutes. The flask was then banged gently 
on the side to help detach the cells and placed under an inverted microscope to 
make certain of cell detachment. Trypsin was then inactivated by adding 10 ml of full 
medium with serum, and after gentle trituration using 10 ml pipette the cell 
suspension was transferred into a 15 ml falcon tube and centrifuged at 1100 rpm for 
5 minutes. The supernatant containing trypsin was discarded and the cell pellet was 
resuspended in 4 ml of prewarmed complete media. The cell suspension was split as 
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recommended into a new T25 flask and media added up to 7 ml. The flasks were 
incubated as before and the media was changed every 2-3 days until 80% 
confluency. 
2.7.5. Cell harvesting 
When cells reached 80% confluency and were ready for harvesting, the media was 
aspirated and 10 ml of 1x PBS was added for washing. Upon aspiration, 2-3 ml of 1x 
PBS was added and the layer of attached cells was scrapped with a rubber cell 
scraper (BD Biosciences). The cells were collected in a 15 ml falcon tube and 
centrifuged at 1100 rpm for 5 minutes. The supernatant was discarded and cells 
were either lysed immediately or the cell pellet was placed on dry ice and transferred 
to a deep freeze (-80 C) for storage until time for protein/RNA extraction. 
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2.8. Immunocytochemistry 
2.8.1. Growing MG1361 cells on coverslips 
Round 16 mm coverslips (VWR International) were used to culture the mouse 
MG1361 mammary tumour cell line. The coverslips were first placed in a 12-well 
plate (Thermoscientific) and submerged in absolute ethanol for sterilization. Ethanol 
was aspirated and the coverslips were allowed to air-dry in the laminar flow cabinet. 
They were then rinsed 3 times with sterile ddH2O and allowed to dry. For enhanced 
cell adhesion, the coverslips were coated with a solution of Poly-L-Lysine (PLL) 
(Sigma-Aldrich). About 80 µl of an equal volume mixture of 0.01% PLL and sterile 
ddH2O was applied evenly across the surface of the coverslips. They were then 
incubated at 37 C and 5% CO2, followed by PLL aspiration and air-drying in the 
laminar flow hood. The coverslips were then seeded with the mouse mammary 
cancer cell line MG1361. This was done by taking 80% confluent cells growing in a 
T25 flask and trypsinizing and washing the cells with 1x PBS as above. They were 
then washed with 10 ml of William’s medium E and resuspended in 10 ml of media. 5 
ml of the cell suspension was then added to 15 ml of media and 2 ml of this was 
plated in each of 10 wells that contain the PLL-coated coverslips. Cells were allowed 
to adhere and grow until they reached 80% confluency, at which time they were 
ready for immunostaining. 
2.8.2. Immunostaining of MG1361 cancer cells 
The 80% confluent cells growing on coverslips were transferred into a new 12-well 
plate with about 500 µl of media they were growing in added to prevent drying. They 
were then washed with 1 ml of cold 1x PBS. The PBS was aspirated and cells were 
fixed by adding 4% formaldehyde solution in PBS. The plate was incubated at 4 C 
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for 20 minutes. The fixative was aspirated and the cells were washed with cold 1x 
PBS. The cells were incubated with 1 ml of cold methanol for 5 minutes at room 
temperature. After, the cells were washed 3 times with cold 1x PBS. 10% goat serum 
was applied as blocking buffer with 1 hour incubation at room temperature. After the 
incubation time was up, 100 µl of each of five *primary antibody solutions in 1% 
blocking buffer was pipetted onto a parafilm strip to form a bubble. The blocking 
buffer was then aspirated from the wells and coverslips carefully placed with the cells 
down onto the bubble and incubated at room temperature for 2 hours. Upon 
completion of the 2 hour incubation with primary antibody, the cells were placed back 
in the 12-well plate and washed 3 times with cold 1x PBS. 500 µl of secondary 
antibody solution, containing 1:3000 dilution of each of goat anti-rabbit IgG-Alexa 
fluor 546 (Invitrogen) and goat anti-mouse IgG-Alexa fluor 488 (Invitrogen), was 
added to the cells and incubated for 1 hour in the dark at room temperature. The 
cells were then washed 3 times with cold 1x PBS. 0.1 µg/ml of DAPI solution in 1% 
PBS was applied for 5 minutes at room temperature protected from light. Finally, the 
cells were washed 3 times with cold 1x PBS and mounted on slides using Immuno-
mounts for observation under confocal fluorescent microscopy. 
*Primary antibody solutions 
 Affinity purified rabbit anti-mouse -synuclein (SK23) diluted 1:250 in 1% 
blocking buffer. 
 Affinity purified rabbit anti-mouse -synuclein (SK23) + mouse anti-vimentin 
(BD Pharmigen) both diluted 1:250 in 1% blocking buffer. 
 Affinity purified rabbit anti-mouse -synuclein (SK23) + mouse anti- -tubulin 
(Sigma-Aldrich) both diluted 1:250 in 1% blocking buffer. 
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 Affinity purified rabbit anti-mouse -synuclein (SK23) diluted 1:250 + mouse 
anti--tubulin (Sigma-Aldrich) diluted 1:5000 in 1% blocking buffer. 
 Affinity purified rabbit anti-mouse -synuclein (SK23) diluted 1:250 + mouse 
anti--Actin (Sigma-Aldrich) diluted 1:5000 in 1% blocking buffer. 
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2.9. -synuclein mRNA expression in mouse mammary cancer cell lines  
qRT-PCR utilizing Cyber-green chemistry was used to compare the level of -
synuclein mRNA expression in ErbB2-positive mouse cancer cell line MG1361 to 
that of ErbB2-negative 4T1 and EpH4 mouse cancer cell lines, as well as to Wt-SpC 
(spinal cord) that highly expresses -synuclein. In a separate run, the levels of -
synuclein mRNA expression in N202A, N202E and 4T1 cell lines were compared. To 
this end, total RNA was first isolated from cell pellets and spinal cord tissue using 
Qiagen RNeasy mini kit according to the manufacturer’s protocol (Qiagen). The 
quantity and purity of extracted RNA was assayed by measuring A260 and A280 using 
NanoDrop spectrophotometer (Labtech International). Subsequently, first strand 
synthesis on normalized RNA samples was carried out using random 
hexadeoxynucleotide primers (HP) (Promega). 1 µl of HP (from 0.5 mg/ml stock) was 
added to an eppendorf tube containing 1 µg of RNA in 12 µl of nuclease-free MQ 
H2O. The solution was then incubated at 68 °C for 10 minutes to denature the 
secondary structure of RNA. The tubes were spun briefly and 7 µl of premix solution 
was added (4µl of 5x first strand buffer + 2µl of 0.1 M DTT + 1 µl of 10mM dNTPs). 
They were then incubated at room temperature for 10 minutes to allow binding of 
random primers to template RNA. The tubes were prewarmed in a 39 °C water bath 
for 2 minutes and 1 µl of superscript reverse transcriptase I was added. First strand 
cDNA synthesis was allowed to proceed at 39 °C for 1 hour. Finally, the tubes were 
transferred to ice, 30 µl of nuclease-free MQ H2O added and the samples aliquoted 
into 15 µl and kept at -80 °C until qPCR was performed. 
99 
 
2.10. Western blotting 
2.10.1. Isolation of total protein from cell pellets 
The cell pellet (about 200 µl volume) was used fresh or taken out of the -80 C and 
placed directly on ice. 400 µl of *2x Laemmli buffer without 2-mercaptoethanol was 
added with gentle mixing by pipetting up and down. A homogenizer (or a small 
syringe with a 23G needle) was used to aid lysing the cells. When the lysate was too 
viscous more buffer was added and/or boiling was performed for about 10 mins. A 
portion of the cell lysate (without 2-mercaptoethanol) was used to determine the 
protein concentration using the Bradford assay according to the manufacturer’s 
protocol (Bio-Rad Protein Dc Assay). 100 µl of the cell lysate was transferred to a 
new eppendorf tube and 1.0 µl of 2-mercaptoethanol was added and mixed well. The 
lysate was then boiled at 100 C for about 10 minutes to help denature the total 
proteins, placed on ice for about 5 minutes and kept at -20 C until loading into an 
SDS-PAGE gel for Western blotting. 
*2x Laemmli buffer without 2-mercaptoethanol 
Tris-HCl pH 6.8                                   100 mM 
Glycerol                                    20% 
SDS                                    4% 
Bromophenol blue                                    0.02% 
To prepare 2x Laemmli buffer with 2-mercaptoethanol it was added to a final 
concentration of 0.2 M. 
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2.10.2. Extraction of cytoplasmic protein from mammary tissues 
About 30 mg of frozen tissue was weighed into an eppendorf tube containing 300 µl 
of ice-cold lysis buffer with protease inhibitors added. The tissue was homogenized 
using motorised pestle and resulting homogenate was centrifuged for 10 mins at 
6500 rpm at 4 C. 100 µl of the supernatant was transferred to a new eppendorf tube 
containing 100 µl of 2x Laemmli buffer without 2-mercaptoethanol and mixed well. A 
portion was used to determine the protein concentration using the Bradford assay 
according to the manufacturer’s protocol (Bio-Rad Protein Dc Assay). 100 µl of the 
sample was transferred to a new eppendorf tube and 1.0 µl of 2-mercaptoethanol 
was added and mixed well. The tissue sample was then boiled at 100 C for 10 
minutes, placed on ice for about 5 minutes and kept at -20 C until loading onto an 
SDS-PAGE gel for Western blotting. 
*Lysis buffer with no protease inhibitors 
Tris-HCl   pH 7.5                                 50 mM 
NaCl                                 150 mM 
Triton X-100                                 1% 
For lysis buffer with protease inhibitors, 1 tablet of Complete Mini (Roche) was 
added per 10 ml of buffer just before use, in accordance with the manufacturer’s 
instructions. 
2.10.3. Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-
PAGE)  
Having prepared proteins from cell pellets/mammary gland tissue in SDS loading 
buffer (Laemmli buffer), the samples were loaded into an SDS-PAGE gel for 
separation of proteins according to their molecular weight. For this, a mini-gel 
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apparatus (Bio-Rad) was assembled, and after the gel was set the *electrophoresis 
running buffer was added. Normalized levels of protein samples (15 µg) were 
loaded, with one well loaded with 3 µl of a molecular weight size marker (Fermentas 
PageRuler Plus). The gel was composed of two layers: an upper *stacking layer with 
6% polyacrylamide concentration and a lower *resolving layer with 16% 
polyacrylamide. The gel was run at 200 volts for 50-60 minutes, giving the SDS-
rendered negatively charged polypeptide chains enough time to separate. 
*Stacking gel 
Acrylamide/Bisacrylamide (Sigma-Aldrich)                6% 
Tris-base pH 6.8                155 mM 
SDS                100 mM 
APS (Ammonium Persulfate) (Sigma)                100 mM 
TEMED (Tetramethylethylenediamine) (Fluka)                 3 µl /3 ml of gel solution 
*Resolving gel 
Acrylamide/Bisacrylamide 16% 
Tris-base pH 8.8 312 mM 
SDS 100 mM 
APS  100 mM 
TEMED 5 µl/5 ml of gel solution 
*Electrophoresis buffer 
Tris-base 25 mM 
Glycine (Sigma) 192 mM 
SDS 0.1% 
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2.10.4. Transfer of proteins from the gel onto a PVDF membrane. 
A semi-dry blotting apparatus (Sigma) was used to transfer the separated proteins 
from the mini-gel onto a Hybond-P (Amersham), hydrophobic polyvinylidene 
difluoride (PVDF) membrane. The membrane was cut to the size of the resolving gel 
(5 cm x 8 cm), washed with methanol, rinsed with MQ water and soaked in transfer 
buffer. Two pieces of thick blotting paper were cut to the size of the membrane/gel 
and soaked in *transfer buffer. The semi-dry blotting unit was placed on a level 
bench and a small amount of transfer buffer was applied to the center. A sandwich of 
blotting paper/gel/membrane/blotting paper was assembled and placed in the center. 
Transfer was allowed to run at 100 mA for 90 minutes. At the end of the run, the 
membrane was washed 3x 5 minutes in *TBS-T (Tris Buffered Saline with 0.1% 
Tween 20) to remove methanol and proceed to blocking. The gel was washed with 
water and rocked in few millilitres of Gelcode Blue stain reagent solution 
(Thermoscientific) to confirm protein separation. 
*10x Transfer buffer 
Tris-base 250 mM 
Glycine 1.5 M 
To prepare fresh 1x transfer buffer, 10 ml of 10x transfer buffer was added to 20 ml 
of methanol and 70 ml of ddH2O. 
*TBS-T 
One pouch of Tris Buffered Saline powder pH 8.8 (Sigma) and 10 ml of 10% Tween 
20 were dissolved in a total of 1 L MQ H2O by stirring on a magnetic stirrer for 10 
minutes. 
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2.10.5. Immunodetection 
Before adding the primary antibody, the membrane was blocked with 4% dried 
skimmed milk (Marvel) in TBS-T for 60-90 minutes at room temperature to prevent 
non-specific background binding of the primary and/or secondary antibodies to the 
membrane. The blocked membrane was then incubated with *primary antibody 
solution overnight at 4 °C. The membrane was then washed 3x 10 minutes to 
remove the primary antibody and incubated with *HRP-conjugated secondary 
antibody for 60-90 minutes at room temperature. It was later washed 3x 10 minutes 
to remove the secondary antibody. To detect protein bands, ECL+ Enhanced 
ChemiLuminescence detection system (Amersham) was used according to the 
manufacturer’s protocol. To ensure equal loading of samples, the membrane was 
reprobed with antibody against housekeeping proteins GAPDH or beta-actin. This 
was done by first washing it 3x 5 minutes with TBS-T to remove ECL+ and then 
stripping off antibodies using an *antibody stripping buffer. The membrane was 
incubated in the stripping buffer for 30 minutes at 55 °C and later washed 3x 5 
minutes with TBS-T solution. It was then re-blocked with 4% milk and proceeded as 
above to reveal GAPDH or beta-actin bands. 
*Primary antibody solutions 
 Affinity purified rabbit polyclonal anti-mouse -synuclein (SK23) diluted 
1:1000. 
 Mouse monoclonal anti- GAPDH, clone 6C5, (Santa Cruz Biotechnology) 
diluted 1:5000. 
 Affinity purified rabbit polyclonal anti-human -synuclein (SK109) diluted 
1:500. 
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 Rabbit polyclonal beta-actin – loading control (ab8227, Abcam) diluted 
1:1000. 
*HRP-conjugated Secondary antibodies (Amersham) 
 Peroxidase conjugated anti-mouse immunoglobulin antibody 
 Peroxidase conjugated anti-rabbit immunoglobulin antibody 
*Antibody stripping buffer 
Tris-HCl pH 6.8 62.5 mM 
SDS 2% 
2-mercaptoethanol (added just before use) 100 mM 
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2.11. Extraction and purification of -synuclein protein from human 
breast cancer cell line SKBR3. 
2.11.1. Protein precipitation with Ammonium Sulfate 
All of the extraction steps were carried out on ice to prevent protein degradation. 
SKBR3 cells were cultured and harvested as above, with about 1.9 grams of cell 
pellet was produced and kept at -80 °C until lysis. The pellet was homogenized in 
10ml of lysis buffer containing Complete Mini Protease Inhibitors (Roche) using 
glass/Teflon homogenizer. The homogenate was centrifuged at 4° C for 20 minutes 
at 13,000 rpm and the supernatant was transferred to a new tube. Enough buffer (50 
mM Tris-HCl pH 7.5) was added to resuspend the pellet and a 30 µl aliquot was 
taken from both the supernatant (Lysate fraction) and the pellet (Nuclear fraction) for 
Western blot analysis of -synuclein content. Proteins were precipitated from the 
supernatant by gradual addition of 0.6 volume of saturated (4M) (NH4)2SO4 with 
gentle mixing. The solution was incubated on ice for 10 minutes. It was then 
centrifuged at 4° C for 20 minutes at 13000 rpm and the supernatant was transferred 
to a new tube. Enough buffer (50 mM Tris-HCl pH 7.5) was added to resuspend the 
pellet and a 30 µl aliquot was taken from both the supernatant (1.5 M supernatant 
fraction) and the pellet (1.5 M pellet fraction) for Western blot analysis. A calculated 
amount of (NH4)2SO4 crystals was added with gentle swirling to increase the 
concentration to 2 M and the solution was incubated on ice for 10 minutes. It was 
then centrifuged at 4° C for 20 minutes at 13000 rpm and the supernatant was 
transferred to a new tube. Enough buffer (50 mM Tris-HCl pH 7.5) was added to 
resuspend the pellet and a 30 µl aliquot was taken from both the supernatant (2 M 
supernatant fraction) and the pellet (2 M pellet fraction) for Western blot analysis.  
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This process of gradual increase in (NH4)2SO4  concentration to precipitate proteins 
was repeated twice to obtain 2.5 M and 3 M fractions of both supernatant and pellet, 
with aliquots taken for Western blot monitoring of -synuclein content. All fractions 
were kept at -80° C until further purification. 
2.11.2. Gel Filtration Chromatography 
The 2 M pellet fraction containing -synuclein, resuspended in 4.5 ml of 50 mM Tris-
HCl pH7.5 buffer, was defrosted on ice and centrifuged at 4° C for 20 minutes at 
13000 rpm to eliminate any particulate matter. The supernatant was transferred to a 
new tube and a 30 µl aliquot was taken for Western blot analysis of -synuclein 
content. A Superdex 75 10/600 GL column (GE Healthcare) was used to fractionate 
the protein sample as a first step of purification. The column was mounted on an 
AKTA prime plus system (GE Healthcare), a fully automated liquid chromatography 
system. A PrimeView software was used to acquire and evaluate data 
communicated from the AKTA purifier. Prior to applying the sample, the column was 
washed with 5 column volumes of MQ water to remove the 20% ethanol it was 
stored in. It was then equilibrated with 5 column volumes of gel filtration buffer (50 
mM Tris-HCl pH 7.5/100 mM NaCl). Both MQ water and buffer were degassed and 
filtered before use. The 4.5 ml sample was applied at 3 runs of 1.5 ml each. The 
column was run at a flow rate of 1 ml/min and over fifty 2 ml-fractions were collected 
for each run. The fractions were kept in the cold room as they were collected and 
aliquots were taken for Western blot analysis of -synuclein content.  
2.11.3. Ion Exchange Chromatography 
6 fractions from the gel filtration run above that were positive for -synuclein were 
combined (for a total of 12 ml sample) for further purification using an anion 
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exchange matrix (Resource-Q column from GE Healthcare). The same fully 
automated AKTA purifier system was used along with the complementary PrimeView 
software. The column was first washed with 5 column volumes of MQ water, applied 
at 4 ml/min, to remove the 20% ethanol it was stored in. It was then washed with 5 
column volumes of binding buffer (50 mM Tris-HCl pH 7.5/100 mM NaCl). MQ water, 
binding buffer and elution buffer (50 mM Tris-HCl pH 7.5/1 M NaCl) were degassed 
and filtered before use. The column was then washed with 5 column volumes of 
elution buffer followed by equilibration with 5 column volumes of binding buffer. The 
sample was loaded at a flow rate of 4 ml/min and 12 ml of flow through was 
collected. The column was washed with binding buffer and 40 ml of wash was 
collected. A linear gradient elution was then performed with an increasing ionic 
strength of up to 0.5 M NaCl, with fifty five 3 ml-fractions collected. This was followed 
by a step elution to 1 M NaCl ionic strength to elute remaining bound protein, with 
fifteen 3 ml-fractions collected. The column was finally washed with 5 volumes of 
binding buffer, then 10 volumes of MQ water and last washed with 5 volumes of 20% 
ethanol for storage. Aliquots were taken from flow through, wash and eluted fractions 
for Western blot analysis of -synuclein content. 
2.11.4. Dialysis 
Dialysis tubing, high retention seamless cellulose tubing (Sigma), with a molecular 
weight exclusion of 12 kDa was used to remove smaller molecules and salts. The 
tubing was cut into 15 cm segments which were then washed by boiling submerged 
for 10 minutes in a solution of 100 mM EDTA pH 8.0 (Sigma). The tubing segment 
was clipped at one end, the sample pipetted in and clipped at the other end. It was 
then placed in a large beaker containing 2 l of 5 mM Ammonium Carbonate (Sigma) 
to be dialysed overnight at 4°C with constant stirring. The dialysis solution was 
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decanted and a fresh one added for a further 3-hour dialysis. The sample was then 
transferred to a 50 ml falcon tube, placed on dry ice and was freeze-dried overnight. 
The lyophilized sample was resuspended in 200 µl of 10 mM Tris-HCl pH 7.5. 30 µl 
aliquots were taken before and after dialysis as well as after lyophilisation for 
Western blot analysis of -synuclein content. 
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2.12. Enzymatic testing of purified -synuclein for glycosylation and 
phosphorylation. 
2.12.1. Enzymatic glycosylation test. 
N-Glycosidase F (PNGase F) (BioLabs), an amidase that cleaves between the 
innermost N-Acetylglucosamine (GlcNAc) and Asparagine, was used according to 
the manufacturer’s protocol to investigate whether -synuclein was post-
translationally modified by N-linked glycosylation. 9 µl of purified -synuclein (about 1 
µg) was added to an eppendorf tube containing 1 µl of 10x glycoprotein denaturing 
buffer and incubated at 100 °C for 10 minutes. Upon denaturation, 2 µl of 10x G7 
reaction buffer, 2 µl of 10% NP40, 6 µl of MQ water and 1 µl of PNGase F enzyme 
(500 U) were added. The reaction was then incubated at 37 °C for 1 hr. After, 7 µl of 
4x Laemmli buffer was added, tubes incubated at 100 °C for 5 minutes to deactivate 
the enzyme and 15 µl was loaded onto a 13% SDS-PAGE. Upon electrophoresis, 
the samples were immunoblotted and processed as outlined above (sections 2.10.4 
for and 2.10.5) for detection of -synuclein. 
2.12.2. Enzymatic phosphorylation test. 
Shrimp alkaline phosphatase (SAP) (Promega) was used to remove any phosphate 
groups may have been added as post-translational modification to -synuclein. 9 µl 
of purified -synuclein (about 1 µg) was added to an eppendorf tube containing 2 µl 
of 10x SAP buffer, 2 µl of SAP enzyme (10 U) and 7 µl of MQ water, and incubated 
at 37 °C for 30 minutes. The reaction was then inactivated by incubation at 65 °C for 
15 minutes. After, 7 µl of 4x Laemmli buffer was added and 15 µl was loaded onto a 
13% SDS-PAGE. Upon electrophoresis, the samples were immunoblotted and 
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processed as outlined above (sections 2.10.4 for and 2.10.5) for detection of -
synuclein. 
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2.13. Statistical analysis 
As the sample sizes used for both -synuclein Wt and -synuclein KO experimental 
females were small (N=21 and N=22, respectively), non-parametric statistics was 
used. For this purpose, the Wilcoxon’s rank sum test was performed using Minitab-
16 software program. This was used to analyse the significance of differences 
between the -synuclein Wt and -synuclein KO experimental females in the different 
animal parameters collected: number of palpable tumours; age at parity; age at 
sacrifice; age at detection of the first palpable tumour; age at detection of all palpable 
tumours; age at which tumours reached a size of 250 mm3; age required for tumours 
to grow from a size of 250 mm3 to a size of 1500 mm3. The level of significance used 
was α=0.05, i.e, if the calculated p-value was less than or equal to 0.05 then the null 
hypothesis of no significant difference between the two compared medians was 
rejected in favour of the alternative hypothesis that the difference was significant and 
thus due to the knocking out of -synuclein from the genome. 
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Results 
Chapter 3. Expression of -synuclein in mouse and human 
mammary tumour cell lines and its subcellular localization in the 
murine mammary tumour cell line MG1361. 
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3.1. Expression of -synuclein in mouse and human mammary tumour 
cell lines 
3.1.1. Introduction 
Previously, an observation was made in our lab correlating the expression of -
synuclein with that of ErbB2/Neu/Her2 receptor tyrosine kinase in the mouse 
mammary tumour cell line MG1361. This cell line was originally established from a 
mammary adenocarcinoma isolated from the transgenic breast cancer mouse model 
FVB-Tg(MMTV-ErbB2)NK1Mul/J which was developed by the Jackson laboratory 
and herein referred to shortly as “NK” (Sacco et al., 1998). This transgenic mouse 
strain expresses an activated form of the rat ErbB2 (c-neu) to yield a constitutively 
active receptor. To confirm this correlation, further mammary tumour cell lines that 
are known to be either positive or negative for ErbB2 were investigated for -
synuclein expression. Quantitative RT-PCR was performed to compare the relative 
levels of -synuclein expression in two ErbB2-negative mouse mammary tumour cell 
lines (the tumourigenic 4T1 cell line and the nontumourigenic EpH4 cell line) and the 
ErbB2-positive tumourigenic MG1361 cell line. RNA extracted from the mouse spinal 
cord, a tissue with high levels of -synuclein expression, was used as a positive 
control. 
In a separate set of experiments, -synuclein mRNA and protein expression were 
compared in two murine mammary tumour cell lines (N202A and N202E) using 
quantitative (q)RT-PCR and Western blotting, respectively. These two cell lines were 
established from a mammary tumour isolated from a transgenic breast cancer 
mouse model (FVB/N-Tg(MMTVneu)202Mul/J), which was developed by the 
Jackson laboratory and herein referred to shortly as “N202”. This transgenic strain 
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expresses the wild type rat ErbB2 gene. The N202A cell line expresses high levels of 
the ErbB2 receptor, while the N202E cell line, which was actually derived from 
N202A, has downregulated expression of the receptor. This study was also extended 
to a panel of 9 human breast cancer cell lines and 1 ovarian cancer cell line, SKOV3. 
Some of these cell lines are known to express very low levels or do not express at all 
ErbB2 (BT20, MDA-MB-468, MDA-MB-231, MCF-7, GI101 and HS578T), while other 
lines express relatively high levels of ErbB2 (BT474, SKBR3, T47D and SKOV3). 
3.1.2. Results and discussion 
Figure 3.1 below compares the expression of -synuclein in different murine 
mammary tumour cell lines and wild type spinal cord (WT-SpC), with the 
tumourigenic 4T1 cell line set as control. The graph clearly shows that the 
transformed, non-tumourigenic cell line EpH4 had the same relatively very low level 
of expression as that of the control tumourigenic 4T1 cell line. Both of these cell lines 
are known to be ErbB2-negative. However, expression in the ErbB2-positive 
MG1361 cell line was 83-fold greater than in the control 4T1, and about the same as 
in the spinal cord tissue from wild type C57BL6 mice that expresses high levels of -
synuclein. The MG1361 cell line was originally established from the NK model that 
expresses a constitutively active mutant form of the receptor. This points to a 
correlation between ErbB2 positivity and -synuclein expression, suggesting a 
possible involvement of -synuclein in some aspect of ErbB2 function. This 
suggestion was strengthened when two closely related ErbB2-expressing mouse 
mammary tumour cell lines were investigated. N202A and N202E cell lines were 
established from a mammary adenocarcinoma isolated from a transgenic mouse line 
expressing rat ErbB2 (N202 model). N202A expresses relatively high level of the 
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ErbB2 proto-oncogene, while N202E, derived from N202A, has undergone 
downregulation of ErbB2 expression. 
 
 
             
Figure 3.1. Quantitative RT-PCR comparison of -synuclein expression in murine 
mammary tumour cell lines positive or negative for ErbB2 receptor. qRT-PCR was 
used to determine the relative mRNA expression levels of -synuclein in the ErbB2-
positive mouse mammary tumour cell line MG1361 and the ErbB2-negative mouse 
mammary tumour cell lines EpH4 and 4T1. The level of --synuclein mRNA 
expression in 4T1 was set as control and the spinal cord tissue from wild type 
C57BL6 mouse strain (WT-SpC) was used as a positive control for high levels of -
synuclein expression. The run was made with three replicates (N = 3) and error bars 
in the figure correspond to standard error of mean. NA = non-applicaple.  
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Figure 3.2 below (right panel) shows that the expression level of -synuclein mRNA 
in N202A is approximately twice that in N202E, and that both cell lines had about 18- 
and 10-times higher expression than the control ErbB2-negative 4T1 cell line, 
respectively. This was confirmed at the protein level as shown in the left panel of the 
figure, where appreciably higher levels of the protein was detected by the mouse -
synuclein specific antibody SK23 in N202A compared to in N202E cell line. 
Surprisingly, the detected -synuclein band in the western blot appeared at the 
approximately 30 kDa molecular weight position, which is roughly twice the size of 
the normal (monomer) band of ~18 kDa, a pattern also exhibited by the tumour 
tissues arising from the N202 mouse model that these cell lines were originally 
established from (as will be seen later in chapter 4). 
Furthermore, to investigate whether this correlation between -synuclein and ErbB2 
expression exists in human breast cancer cell lines, a panel of 9 human breast 
cancer cell lines and 1 ovarian cancer cell line, SKOV3, were investigated. As seen 
in figure 3.3, -synuclein protein was not detected in the cell lines that are known to 
express very low levels of ErbB2 or do not express it at all (MDA-MB-468, MDA-MB-
231, MCF-7, GI101 and HS578T), with one exception being the cell line BT20 where 
-synuclein appeared mostly at the monomer position (~18 kDa) but also at the 
approximately 30 kDa position. The nature of this band is not known but based on 
molecular weight it may be a result of -synuclein protein dimerization, although post-
translational modifications and splice variation could not be excluded. In the 
remaining breast cancer cell lines, -synuclein was detected mostly as a presumable 
dimer in BT474 and SKBR3, and mostly as a monomer in T47D and BT20. In the 
ovarian cancer cell line SKOV3 the protein appeared as both monomer and dimer. 
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Thus, the human cancer cell lines that are known to be ErbB2 positive expressed -
synuclein at either or both forms. Higher molecular weight bands, mostly as trimers 
according to molecular weight, were also detected on the western blots. 
 
 
 
           
Figure 3.2. Immunodetection of -synuclein protein expression in N202 murine 
mammary tumour cell lines. Left panel: Western blot comparing -synuclein protein 
expression in mouse mammary cancer cell lines N202A, that overexpresses ErbB2, 
and N202E, that has downregulated ErbB2 expression. Red arrows point to -
synuclein protein bands which are detected only at the presumable dimer position. 
Right panel: qRT-PCR revealing -synuclein mRNA expression levels of N202A and 
N202E cell lines relative to the ErbB2 negative breast cancer cell line 4T1. The run 
was made with three replicates (N = 3) and error bars in the figure correspond to 
standard error of mean. 
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This appearance of oligomers has been reported by Zhang and co-workers who also 
found endogenous -synuclein to exist in different ratios of dimers and monomers but 
mostly as a monomer in the cell lysate of A2780 human ovarian cancer cell line and 
mostly as a dimer in mouse brain tissue lysate. In the cell lysate of T47D breast 
cancer cell line, oligomers (mostly trimers) of -synuclein were only detected in the 
assay pellet that contained the cytoskeleton, but not in the supernatant which mainly 
represented the cytosolic cellular compartment where only monomers were detected 
(Zhang et al., 2010). 
Thus, the correlation between -synuclein and ErbB2 positivity seems to hold in the 
human cancer cell lines as well. This lends further support to the possible 
involvement of -synuclein in some aspect of ErbB2 function, and thus supports the 
use of the transgenic ErbB2-overexpressing NK model to investigate the effect of -
synuclein deletion on ErbB2-induced mammary gland tumourigenesis. 
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Figure 3.3. Immunodetection of -synuclein protein expression in 9 human breast 
cancer cell lines. Two Western blots (A & B) showing -synuclein protein expression 
in 9 human breast cancer cell lines (SKOV3 in blot A is an ovarian cancer cell line, 
and NP12/95 in blot B is a brain tissue loaded as a positive control for high -
synuclein protein expression). The orange, red and green arrow heads point to the 
monomer, doublet and triplet forms of the protein, respectively. Cell lines that are 
ErbB2 positive, with the exception of BT20 that expresses very low levels of ErbB2, 
also express appreciable levels of -synuclein. 
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3.2. Subcellular localization of -synuclein in the murine mammary 
tumour cell line MG1361 
3.2.1. Introduction 
Most literature revealed that -synuclein is localized to the cytoplasm. However, few 
reports claimed that the protein may localize to various subcellular structures and 
that it may even translocate to the nucleus if the cell was subjected to stress 
conditions. To investigate the subcellular localization of -synuclein in mammary 
tumour cells, the line MG1361 was selected due to the fact that it was originally 
established from the same NK mouse model used for in vivo experiments in the 
current study. The cells were grown in vitro on coverslips and fluorescent 
immunocytochemistry technique was used to stain -synuclein protein as well as 
other cellular components constituting parts of some subcellular structures. These 
included -tubulin as a part of the centrosome, α-tubulin as a part of the midbody and 
spindle fibers, and β-actin as a part of the cytoskeleton. This would enable detection 
of any colocalization -synuclein may have with the above components and thus 
reveal possible involvement in relevant biological processes such as cell division and 
organization of the cytoskeleton. 
3.2.2. Results and discussion 
Figure 3.4 below shows cytoplasmic localization of -synuclein in dividing murine 
cancer cell line MG1361. -synuclein was fluorescently stained in red in the 
cytoplasm of non-dividing as well as dividing cells. It did not appear to colocalize with 
-tubulin, which stained in green and appeared at the centrosomal region of dividing 
cells. Moreover, figure 3.5 shows a dividing cell in the stage of cytokinesis with -
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synuclein stained in red and localized to the cytoplasm. -synuclein did not appear to 
localize to the midbody where the constituent α-tubulin was stained in green.  
 
 
 
             
Figure 3.4. Immunofluorescent detection of -synuclein and -tubulin in dividing 
murine MG1361 cells. Immunofluorescent image (630x) of a cell in an anaphase of 
the cell cycle. -synuclein appears stained in red with cytoplasmic localization. It 
does not appear to colocalize with -tubulin, which appears stained in green as a part 
of the centrosomes. The chromosomes are counterstained with DAPI (blue). 
  
122 
 
 
 
 
             
Figure 3.5. Immunofluorescent detection of -synuclein and α-tubulin in a dividing 
murine MG1361 cell. Immunofluorescent image (630x) of a cell at late cytokinesis 
stage of the cell cycle. -synuclein appears stained in red and localized to the 
cytoplasm. It does not appear to localize to the midbody region where α-tubulin 
appears stained in green. The chromosomes are counterstained with DAPI (blue). 
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These results are consistent with most other studies showing cytoplasmic 
localization of -synuclein. However, one group reported that, in the interphase of 
primary cultures of human optic nerve astrocytes, bovine retinal epithelial cells and 
human retinoblastoma Y79 cell line, -synuclein could be present in the perinuclear 
space and bound to centrosomes. They also reported that, in late mitosis of human 
astrocytoma cell line U373 and melanoma cells OM431 and C8161, -synuclein 
protein was observed to lose the association with centrosomes and redistribute to 
the midbody in telophase (Surgucheva et al., 2006; Surguchov et al., 2001). The 
different results could be due to different behaviours of -synuclein in different cell 
types and/or to different conditions of in vitro cell growth. 
Figure 3.6 depicts α-tubulin fluorescently stained in green as a part of the mitotic 
spindle in a dividing cell at metaphase stage. -synuclein, stained in red, appears to 
have cytoplasmic cellular localization but does not seem to colocalize with α-tubulin 
in the microtubule spindle fibers. The Surguchov group claimed that -synuclein 
protein bound to the spindle poles in the mitotic phase of human retinoblastoma Y79 
cells. Results of our study, however, clearly demonstrate that at least in MG1361 
cells -synuclein is not associated with the spindle poles. In figure 3.7, an 
immunofluorescent image shows β-actin stained in green as a part of the 
cytoskeleton at the cell periphery. No colocalization was observed for -synuclein 
and β-actin, indicating that the former does not interact with β-actin in both dividing 
and nondividing MG1361 cells grown under such in vitro conditions. 
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Figure 3.6. Immunofluorescent detection of -synuclein and α-tubulin in dividing 
murine MG1361 cells. Immunofluorescent image (630x) showing cytoplasmic 
localization of -synuclein that appears stained in red. -synuclein is not seen 
associated with α-tubulin which appears stained in green as a part of the mitotic 
spindle. The chromosomes are counterstained with DAPI (blue). 
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Figure 3.7. Immunofluorescent detection of -synuclein and β-actin in murine 
MG1361 cells. Immunofluorescent image (400x) showing β-actin stained in green as 
a part of the cytoskeleton at the cell periphery. -synuclein is stained in red and 
appears to have cytoplasmic localization with no association with β-actin. The 
chromosomes are counterstained with DAPI (blue). 
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Chapter 4. Expression of -synuclein in normal and tumourous 
mammary gland tissue in mouse breast cancer models 
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4.1. Introduction 
-synuclein was reported to be aberrantly expressed in a large percentage of 
advanced infiltrating breast carcinomas, compared to normal tissue and benign 
tumours where its levels were absent or hardly detectable, and was thus named 
breast cancer-specific gene1 (BCSG1) (Ji et al., 1997). Since then, the possible role 
of -synuclein in mammary gland tumourigenesis has been investigated mostly using 
in vitro culture systems. For the most part, these systems utilized human breast 
cancer cell lines and mouse mammary tumour cell lines in which -synuclein 
expression was either upregulated or downregulated in order to reveal any effects on 
the growth, proliferation, survival and metastasis of the cancerous cells. The 
expression of -synuclein in mouse mammary tumours developed in mice modelling 
human breast cancer was not however investigated directly. 
In this study, immunohistochemistry and western blotting techniques were used to 
investigate -synuclein expression in tumours isolated from three mouse models of 
breast cancer, the two ErbB2-positive transgenic NK and N202 models, and the Blg-
Cre+ BRCA2fl/fl p53fl/fl double mutant model. The transgenic NK model expresses the 
activated form of rat ErbB2 (c-neu) receptor tyrosine kinase oncogene, while the 
transgenic N202 model expresses the wild-type rat ErbB2 proto-oncogene, both 
under the control of the mouse mammary tumour virus (MMTV) promoter that targets 
the expression to the mammary gland epithelium. The Blg-Cre+ BRCA2fl/fl p53fl/fl 
model houses conditional double deletions of BRCA2 and P53 genes in the 
mammary epithelium, triggered by the Cre-recombinase expressed under control of 
the mammary gland specific β-lactoglobulin (Blg) promoter. -synuclein expression 
was also investigated in normal mammary gland tissue from FVB mouse strain by 
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immunohistochemistry to determine which cell types do express the protein. This 
strain constitutes the genetic background of the NK model used in the in vivo 
experiments and into which the KO -synuclein allele was bred. 
4.2. Results and discussion 
Figure 4.1 below shows immunohistochemical staining for -synuclein protein in a 
normal FVB mouse mammary gland. 
 
 
         
Figure 4.1. Immunohistochemical staining for -synuclein in mouse normal mammary 
gland. Two adjacent sections of a normal mammary gland from FVB mouse strain 
were counterstained with H&E. Right panel: staining with antibodies against mouse 
-synuclein (SK23) revealed expression in the thin cytoplasmic layer of adipocytes 
(block arrow) but not in the ductal epithelial cells (thin arrow). Left panel: as a 
negative control for staining specificity, the adjacent section was incubated only with 
secondary antibody. Both microscope images were taken at 400x of magnification. 
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It can be seen that -synuclein is not detected in the epithelium lining the mammary 
ducts, indicating that it is not expressed in the normal epithelium of the mammary 
gland (or if expressed then at undetectable levels). The white adipocytes making up 
most of the gland stroma, however, show very clear specific staining of -synuclein in 
the narrow cytoplasmic strip. -synuclein has been reported to be expressed in 
subcutaneous and visceral adipose tissue and to be increased with obesity, and 
postulated to have a role in the differentiation and physiology of adipocytes (Oort et 
al., 2008). In the current study, -synuclein staining was also observed in the 
endothelial cells lining some of the vasculature and in nerve fibers innervating the 
mammary glands investigated. 
Figure 4.2 below shows immunohistochemical detection of -synuclein protein in 
epithelia-derived cells in a mammary gland tumour obtained from the NK model 
mouse. This abnormal expression was found in about 18% (5/27) of tumours 
investigated in both ErbB2-overexpressing models, 2/14 tumours of N202 model and 
3/13 tumours of NK model. This percentage of -synuclein-positive tumours is 
comparable to a published study on human tumour tissue by Guo and co-workers 
(Guo et al., 2007). They reported a significant correlation between -synuclein 
aberrant expression and ErbB2 status (P<0.001): about 24% (37/151) of ErbB2-
positive tumour samples expressed -synuclein, whereas only about 10% (21/207) of 
ErbB2-negative tumour samples expressed -synuclein. This correlation might point 
to an involvement of -synuclein in some aspect of ErbB2 activity, as already noted 
in the previous chapter presenting the results from human and mouse mammary 
tumour cell lines. In another study, however, no correlation was found between 
ErbB2 positivity and -synuclein expression in breast tumour samples (P=0.46): 
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about 32% (8/25) of ErbB2-positive tumour samples aberrantly expressed -
synuclein, compared to about 37% (21/56) of ErbB2-negative tumour samples 
expressing -synuclein (Wu et al., 2007). 
 
 
     
Figure 4.2. Immunohistochemical staining for -synuclein in tumour and adjacent 
normal mammary gland from NK mouse model. Immunohistochemical staining for -
synuclein (A and B) and H&E staining (C) of three adjacent sections of tumour (thin 
arrows) and adjacent normal mammary gland tissue (block arrows). A: epithelia-
derived tumour cells (thin arrows) and adipocytes of adjacent normal tissue (block 
arrow) are positively stained with antibodies against mouse -synuclein (SK23). B: as 
a negative control for staining specificity, the section was incubated only with 
secondary antibody. C: H&E stained section showing epithelia-derived tumour cells. 
Microscope images were taken at 40x of magnification. 
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Figure 4.3 below shows a Western blot of normal (N) and tumour (T) tissues 
obtained from the ErbB2-overexpressing N202 model investigated for -synuclein 
expression. The normal mammary gland tissue samples showed considerably high 
levels of the protein (~18 kDa monomer) as they are made up mostly of adipocytes 
which are known to express high levels of -synuclein. The tumour tissues, however, 
had no or very little expression of the monomer protein as they are made up almost 
exclusively of highly dividing epithelial tissue. However, an interesting observation 
was the consistent appearance of bands at ~30 kDa size that were much more 
intense in the tumour than in the normal tissues. As already noted in the previous 
chapter, the nature of these bands is not known but based on molecular weight it 
may be a result of -synuclein protein dimerization, although post-translational 
modifications and splice variation could not be excluded. 
The appearance of this presumably dimer form of -synuclein has been reported in a 
study by Zhang and co-workers investigating a role of the protein in microtubule 
regulation. They reported significant amounts of the dimer form in their in vitro 
assays that demonstrated the ability of -synuclein to promote tubulin polymerization 
and to bind preformed microtubules. This study showed that -synuclein may act as 
a microtubule-associated protein and suggested that it may crosslink individual 
microtubules into bundles by dimerizing. Endogenous -synuclein was also found to 
exist as dimers and monomers to different extents, mostly as a monomer in the cell 
lysate of A2780 human ovarian cancer line and mostly as a dimer in mouse brain 
tissue lysate. In the cell lysate of T47D breast cancer line, oligomers (mostly trimers) 
of -synuclein were only detected in the assay pellet that contained the cytoskeleton, 
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but not in the supernatant which mainly represented the cytosolic cellular 
compartment where only monomers were detected (Zhang et al., 2010). 
 
 
 
         
Figure 4.3. Immunodetection of -synuclein in tumour and normal mammary gland 
from N202 mouse model. Immunoblot showing -synuclein expression in normal (N) 
and tumour (T) mammary gland tissues: the upper rectangle box (aqua block arrow) 
shows longer exposure of the ~ 30 kDa (doublet) region of the same western blot. 
Orange and red arrow heads point to the monomer and doublet band positions, 
respectively. 
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It is probable that some of the expression detected in the tumour tissues came from 
the nerve fibers and endothelial cells of arterioles vascularizing the tumours, as well 
as from adipocytes that may have been included from adjacent adipose tissue. 
However, it is more likely to have come mostly from the tumourous epithelial cells 
since the immunoblot bands appear only at the dimer position, as in the ErbB2-
positive N202A and N202E breast cancer cell lines (figure 3.2) that were actually 
derived from this N202 mouse model. Also, the presumable dimer bands are much 
more intense in the tumours than in the normal gland tissues. This is supported by 
the fact that in all 27 ErbB2-positive tumours -synuclein was detected only as a 
dimer, whereas in all normal mammary gland tissues it was detected mostly as a 
monomer which is the form seen in adipocytes. 
This detection of -synuclein at the dimer position was also observed in 15 tumours 
isolated from the Blg-Cre+ BRCA2fl/fl p53fl/fl mutant mice, as can be seen in the 
representative figure 4.4 below. In 3 of these tumour tissues, however, -synuclein 
expression appeared very intense at the monomer band as well. This is probably 
due to inclusion of adjacent normal gland tissue, containing mostly adipocytes, 
during tumour harvest. However, this pattern of expression at both monomer and 
dimer states was also observed in some of the human breast cancer cell lines 
already presented in chapter 2 where expression was detected at either or both 
bands. 
In an attempt to investigate the nature of the presumably dimer form, -synuclein 
protein was isolated from the breast cancer cell line SKBR3, which expresses the 
protein mostly as a dimer. The protein was purified, as outlined in the Materials and 
Methods chapter, and then subjected to enzymatic reaction tests for N-linked 
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glycosylation and phosphorylation. As can be seen in figure 4.5, the tests failed to 
detect any change in the electrophoretic mobility of -synuclein, thus suggesting that 
the two post-translational modification processes are not responsible for the doublet 
band. This result further supports the notion of dimerization and suggests that 
dimerization might be a functional aspect of the small, cytoplasmic -synuclein 
protein. In brief, aberrant expression of -synuclein was detected in mammary 
tumour tissues isolated from both ErbB2-positive models (N202 and NK) as well as 
from Blg-Cre+ BRCA2fl/fl p53fl/fl breast cancer model, with -synuclein expressed 
mostly as a dimer appearing at the ~30 kDa position in the Western blots. 
             
Figure 4.4. Immunodetection of -synuclein in tumour and normal mammary glands 
from Blg-Cre+ BRCA2fl/fl p53fl/fl double mutant mouse model. Immunoblot showing -
synuclein expression in normal (N) and tumour (T) mammary gland tissue: the upper 
rectangle box (blue block arrow) shows longer exposure of the doublet region of the 
same Western blot. Orange and red arrow heads point to the monomer and doublet 
band positions, respectively. 
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Figure 4.5. Immunoblot detection of purified -synuclein before and after reactions of 
enzymatic dephosphorylation and deglycosylation tests. M: protein from T47D cell 
line with mostly monomer, but also dimer and trimer forms, used as a marker. 1: 
purified -synuclein from SKBR3 cell line (reaction substrate source) loaded as 
control. 2 and 3: -synuclein after incubation with reaction components at 37 C for 1 
hour without (2) and with (3) PNGase F amidase enzyme. No difference was 
observed in SDS-PAGE electrophoretic mobility as protein was detected in the 
presumable dimer form, thus suggesting exclusion of N-linked glycosylation as a 
post-translational modification. 4 and 5: -synuclein detected before (4) and after (5) 
alkaline phosphatase treatment, with no resultant change in SDS-PAGE 
electrophoretic mobility. 
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Chapter 5. Effect of -synuclein gene deletion on the normal 
development of mouse mammary gland 
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5.1. Introduction 
To investigate any possible role of -synuclein in mammary gland tumourigenesis it 
is imperative to explore its effect on the normal development of mammary gland. To 
this end, a subset of the FVB -synuclein KO and Wt mice generated at the end of 
stage I of breeding of the experimental cohorts (figure 2.1-control groups) were 
multiplied and used to investigate the effect of -synuclein deletion on the normal 
development of the mammary gland. Virgin females at 2, 3 and 13 months of age 
were sacrificed and the abdominal pair (L4 and R4) of mammary glands were 
dissected, one used for whole mount investigation and the other for H&E-stained 
section histological investigation. 6 females of each genotype (Wt and KO) were 
sacrificed per developmental time point. This would show any effect of -synuclein 
ablation on the dynamic process of ductal branching morphogenesis as this process 
begins mostly with the onset of puberty, which takes place at about 3-4 weeks of 
age. Whole mount and H&E-stained section histological investigations were also 
carried out on 14.5 day-gestating mammary glands obtained from females at 16 
weeks of age. This would reveal any effect of -synuclein ablation on lobuloalveolar 
development, a stage that holds massive tissue remodelling involving extensive 
proliferation of the epithelial ducts and differentiation of alveoli. 
5.2. Results and discussion 
-synuclein was reported to play a role in efficient ER- signalling. It was shown to 
be a component of the heat shock protein (Hsp)-ER- complex, and that it enhanced 
the affinity of ER- to estrogen as it activated the ligand-dependent ER- 
transcriptional activity (Jiang et al., 2004). In the context of mammary gland 
development it has also been reported that ER-α-null mice did not differ from Wt 
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mice up to puberty, at which time their ducts showed no TEBs and failed to invade 
the fatty stroma (Mallepell et al., 2006). Furthermore, mice with conditional KO of 
ER-α in the mammary epithelium at different developmental stages have revealed 
that ER-α signalling is required for both proper ductal branching during puberty and 
normal lobuloalveolar development during late gestation and lactation (Feng et al., 
2007). Robust branching morphogenesis begins with the rising levels of serum 
estrogens at puberty which induce the formation of TEBs at the distal ends of ducts, 
the sites of active cellular proliferation and differentiation during ductal 
morphogenesis. TEBs respond to estrogens and proliferate to elongate the ducts 
and undergo a bifurcation process to form new primary branches (Hinck and 
Silberstein, 2005). This process of ductal elongation and branching continues until 
an age of about 8-10 weeks, when the margins of the fat pad are reached. 
Accordingly, it is plausible to presume that -synuclein might be involved in ER- 
signalling in the TEBs and hence play a role in ductal branching morphogenesis. 
However, as can be seen in figure 5.1 below, investigations of whole mount and 
H&E-stained sections revealed no differences in the structure and extent of ductal 
branching between -synuclein KO and Wt glands of 8- and 12-week old virgin 
females. This indicates that -synuclein is not essential for the process of epithelial 
ductal elongation and branching, but does not necessarily mean that it has no role in 
the process. In fact, transgenic mice overexpressing -synuclein under the control of 
mouse mammary tumour virus (MMTV) promoter showed an effect on mammary 
gland development (Liu et al., 2007b). In their study, whole mount histological 
analysis showed that the transgenic mammary gland exhibited a significant increase 
in ductal branching morphology and terminal end bud density starting at 10 weeks of 
age. This indicated a highly proliferative capacity of epithelial cells at the terminal 
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end buds. This pregnancy-like phenotype was confirmed by H&E-stained sections 
which also showed hyperplasia-like structures in the transgenic mammary glands 
characterized by areas of multilayered epithelium. Therefore, -synuclein may be 
involved in the process of ductal branching morphogenesis as evidenced by the 
transgenic glands overexpressing the protein, but it is not essential for this process 
as its deletion had no effect as evidenced by the KO glands in this current study. 
The same null effect of -synuclein gene ablation on mammary gland ductal 
elongation and branching morphogenesis was observed in 13 month-old virgin 
females. 13 months would be more than long enough to reveal any effects -
synuclein gene ablation may have on ductal elongation and branching as this 
process occurs with each oestrus cycle in the mature virgin mammary gland 
(Sternlicht, 2006). As figure 5.2 clearly shows, no differences were seen in the extent 
of elongation and ductal branching between the -synuclein KO and Wt mammary 
glands as revealed by whole mount and H&E-stained section histological 
investigations. 
A gestating mammary gland undergoes a massive tissue remodelling process 
involving extensive proliferation of the epithelial ducts and differentiation of alveoli. 
Concomitant with this massive proliferation of epithelia, and to make room for such 
development, remodelling features the dedifferentiation of adipocytes whereby they 
lose their lipid droplets and become long projections scattered among the 
lobuloalveoli. As this stage represents the most extensive development of the 
mammary gland, it would be more likely to detect any effect of -synuclein deletion 
on the normal development at this stage. Also, studies of mouse mammary gland 
transcriptional profiles during gestation/lactation/involution cycle demonstrated that  
140 
 
             
Figure 5.1. Effect of -synuclein gene deletion on elongation and ductal branching 
morphogenesis in mammary glands at 8 and 12 weeks of age. Representative 
microphotographs of whole mounts (12.5x; scale bars = 4 mm) and H&E-stained 
histological sections (100x; scale bars = 200 µm) of mammary glands obtained from 
FVB -synuclein KO and Wt virgin female mice at 8 weeks of age (A & B) and 12 
weeks of age (C & D) (N = 6 animals/genotype/developmental point). No differences 
in the structure and extent of elongation and ductal branching morphology were 
observed. 
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Figure 5.2. Effect of -synuclein gene deletion on elongation and ductal branching 
morphogenesis in mammary glands at 13 months of age. Representative 
microphotographs of A: whole mounts (12.5x; scale bars = 4 mm) and B: H&E-
stained histological sections (100x; scale bars = 200 µm) of mammary glands 
obtained from FVB -synuclein KO and Wt virgin female mice at 13 months of age (N 
= 6 animals/genotype). No differences in the structure and extent of elongation and 
ductal branching morphology were observed. 
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the transcriptional levels of -synuclein decrease significantly and concurrently with 
dedifferentiation of mature adipocytes which express high levels of -synuclein. This 
decline proceeds until about day 7-8 of gestation where they reach over 50% of the 
original prepregnant state. Then, despite the continuing dedifferentiation of mature 
adipocytes, the levels start rising until around day 12-13 where they almost reach the 
original levels. They then decrease again significantly to about 4-11% of the 
prepregnant levels and remain so until they start rising back to the original levels with 
the onset of involution and redifferentiation of adipocytes (Clarkson and Watson, 
2003). This intermittent rise between about days 7-13 of gestation might involve a 
role of -synuclein in this remodelling process. 
 Nevertheless, and as can be seen in figure 5.3, it appears that the deletion of -
synuclein had no effect on the extent of ductal branching and differentiation of 
lobuloalveoli as the morphology of both KO and Wt glands changes very similarly 
during gestation. Moreover, -synuclein gene deletion did not produce any effects on 
the differentiation and function of alveoli during gestation and lactation. The -
synuclein KO females developed normally lactating mammary glands: they produced 
milk and nursed their pups to grow as normal as the wild types. Both -synuclein KO 
and Wt mammary glands underwent normal gestation/lactation/involution cycle. In 
brief, deletion of -synuclein had no effect on the normal development of the 
mammary gland. 
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Figure 5.3. Effect of -synuclein gene deletion on ductal branching and lobuloalveolar 
development in gestating mammary glands. Upper two panels: whole mount 
microphotographs of 14.5-day gestating mammary glands (L4) obtained from FVB -
synuclein KO and Wt female mice at 16 weeks of age (N = 6 animals/genotype): No 
differences were found in the structure, ductal branching and lobuloalveolar 
development in the gestating glands (12.5x: scale bars = 2 mm and 25x: scale bars 
= 1 mm). Lower panel: H&E-stained sections of a mammary gland (R4) from the 
same animal confirming no differences in the extent of ductal branching and 
differentiation of lobuloalveoli (scale bars = 500 µm). 
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Chapter 6. Effect of -synuclein gene deletion on ErbB2-induced 
mammary gland tumourigenesis 
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6.1. Introduction 
As described in the General Introduction (Chapter 1), -synuclein has been claimed 
to play a role in mammary gland tumourigenesis. Its overexpression was reported to 
stimulate the growth and proliferation of cancer cells, promote the survival of cancer 
cells and inhibit apoptosis, inhibit the mitotic check point function and thereby 
increase chromosomal instability, and enhance breast cancer cell motility and 
metastasis. The above effects were obtained largely through cell culture systems 
utilizing breast cancer cell lines. In transgenic mice, aberrant expression of -
synuclein stimulated ligand-dependent ER- signalling, leading to a highly 
proliferative pregnancy-like phenotype of mammary epithelial cells and branching 
morphology. Therefore, if -synuclein indeed had an essential role in the 
development of mammary gland tumourigenesis and/or enhancing its progression, 
then abrogation of its expression would be expected to prevent the formation or 
retard the progression of mammary tumours. If such a result was realized then more 
serious efforts would be directed towards exploring the use of -synuclein as a 
biomarker of breast cancer progression and prognosis, and certainly as a target for 
treatment. However, the role of endogenous -synuclein in mammary gland 
tumourigenesis has not been studied in an appropriate in vivo model, and our 
research programme is the first attempt to demonstrate directly whether -synuclein 
is required for the development and/or progression of ErbB2-induced mammary 
tumours. 
As mentioned in chapter 3, the choice of the transgenic ErbB2 model came as a 
result of a previous observation in our lab correlating the expression of -synuclein 
with that of ErbB2 receptor tyrosine kinase in the mouse mammary tumour cell line 
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MG1361. This cell line was originally established from a mammary adenocarcinoma 
isolated from the transgenic breast cancer mouse model FVB-Tg(MMTV-
ErbB2)NK1Mul/J, (NK model) (Sacco et al., 1998). This transgenic mouse strain 
expresses a mutant form of the rat ErbB2 gene (activated ErbB2) under the 
regulation of the mouse mammary tumour virus promoter (MMTV). The mutation 
results in a single amino acid substitution at position 664 from valine to glutamic 
acid, rendering the receptor constitutively active. The transgene is expressed in a 
non-uniform and random fashion in the mammary epithelium leading to stochastic 
formation of multifocal tumours. These tumours develop with rapid kinetics, having a 
short latency of about 5 months, making this breast cancer model an aggressive 
one. Because the hypothesis we were going to test involved the prevention and/or 
retardment of tumour formation in the absence of -synuclein, this model seemed to 
be a good choice for this purpose. 
To investigate the effect of -synuclein gene deletion on the development and 
progression of ErbB2-induced mammary tumours in the NK model, an intensive 
breeding work was undertaken in which -synuclein knockout mice on C57BL6 
genetic background were backcrossed for several generations with FVB mice and 
finally intercrossed with mice of NK model, as outlined in the Materials and Methods 
chapter. This breeding work took approximately two years and produced 21 -
synuclein Wt and 22 -synuclein KO experimental females carrying the activated 
ErbB2 transgene. Two control groups were also produced in the breeding work: a 
basic control group comprising 8 -synuclein Wt and 9 -synuclein KO females to 
control for the spontaneous incidence of mammary gland tumourigenesis; and a 
pregnancy passage control group comprising 11 -synuclein Wt and 14 -synuclein 
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KO females to control for any increased incidence of mammary tumours that may 
occur due to the proliferation of epithelial cells during gestation. 
Animals from the experimental and pregnancy passage control groups were mated 
with non-experimental males at 7 weeks of age. This would further induce the 
transcription of the NK transgene in the experimental females as it is driven by an 
MMTV promoter that responds to elevated levels of progesterone during pregnancy. 
The female mothers were allowed to nurse pups for about 18-20 days. After weaning 
pups, females were monitored for tumour development by palpation 1-2 times 
weekly. The time of tumour detection was recorded, and thereupon measurements 
of tumours (2 perpendicular diameters) were recorded to monitor tumour growth. The 
basic and pregnancy passage control groups, lacking the activated ErbB2 transgene 
and showing no tumour development, were sacrificed at an age of 13.5 months. The 
experimental female animals, with the activated ErbB2 transgene, were sacrificed 
when the longer axis of the biggest palpable tumour reached 20 mm, as required by 
the Home Office regulations. Moreover, the following animal parameters were 
recorded: age at parity (taken as estimated onset of gestation = age at birth giving – 
20 days), age at sacrifice (when the longer axis of the largest palpable tumour 
reached a length of 20 mm) and the number of palpable tumours formed. Upon 
sacrificing the animal, normal and tumourous mammary glands were dissected and 
harvested for histological investigations. Metastasis was investigated by visual 
inspection of body organs at sacrifice and by histological analysis of lung and kidney 
tissues. 
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6.2. Results and discussion 
6.2.1. Deletion of -synuclein gene did not prevent formation of tumours in the 
mammary epithelium by activated ErbB2  
Table 6.1 below shows summary description and tumour incidence in the -synuclein 
Wt and -synuclein KO female mice of the basic control, pregnancy passage control 
and experimental groups.  
 
 Basic Control Group  
(No NK transgene; 
No pregnancy passage; 
sacrificed at 13.5 
months of age) 
Pregnancy Passage 
Control Group 
(No NK transgene; one 
pregnancy passage; 
sacrificed at 13.5 
months of age) 
Experimental Groups 
(Hemizygous NK 
transgene; one 
pregnancy passage; 
sacrificed when a 
tumour diameter 
reached 20 mm)  
Wt N = 8 
No tumours developed 
N = 11 
No tumours developed 
N = 21 
All females developed 
tumours 
KO N = 9 
No tumours developed 
N = 14 
Only 1 female 
developed tumours 
N = 22 
All females developed 
tumours 
Table 6.1. Summary description and tumour incidence in -synuclein Wt and -
synuclein KO female mice of the control and experimental cohorts. 
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In the basic control group, lacking the activated ErbB2 transgene and not passed 
through pregnancy, no tumours were formed in the mammary epithelium of both -
synuclein Wt and -synuclein KO female mice during an observation time of 13.5 
months. In the pregnancy passage control group, also lacking the activated ErbB2 
transgene, none of the -synuclein Wt females developed any tumours and only 1/14 
(7%) of the -synuclein KO females developed a mammary tumour which was 
detected at an age of 268 days. This incidence falls within the range of spontaneous 
mammary tumourigenesis in multiparous FVB mice which was recorded to be 14%, 
although spontaneous tumours were reported to be detected at an older age (> 300 
days, mostly between 600-800 days of age) (Huang et al., 2008). Hence, the 
extensive proliferation of mammary epithelial cells during gestation (pregnancy 
passage) did not affect the spontaneous incidence of mammary tumours 
significantly, and this one incidence in the KO group may be considered negligible 
when comparing the effect of -synuclein deletion on mammary tumour formation by 
activated ErbB2 in the experimental females. 
All experimental female cohorts harbouring the hemizygous activated ErbB2 
transgene (21 -synuclein Wt and 22 -synuclein KO females) developed mammary 
tumours regardless of the presence or absence of the functional -synuclein gene. 
Thus, ablation of -synuclein did not prevent induction of mammary gland 
tumourigenesis by the activated ErbB2 transgene in mammary gland epithelium. 
Multifocal tumours were formed in the majority of the 5 pairs of mammary glands in 
most experimental female mice. This is a result of the pattern of expression of the 
activated ErbB2 transgene which is known to occur in a non-uniform and random 
fashion in the mammary epithelium (Muller et al., 1988). The experimental -
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synuclein KO females developed more tumours than the -synuclein Wt ones, with a 
mean number of 12.8 and 10.6 mammary tumours/female mouse, respectively. This 
result is graphically presented in figure 6.1 below. This difference, however, was not 
significant (P = 0.30 using Wilcoxon’s rank sum test). Generally, tumour tissue took a 
greyish white appearance, were mostly soft, had central areas of necrosis and 
contained blood-filled cysts. Figures 6.2 and 6.3 below show photographs of 4 
representatives of each of the -synuclein KO and -synuclein Wt experimental 
females, respectively, dissected immediately upon sacrifice and showing mammary 
tumours at different stages of development in the different glands. Figure 6.4 below 
shows microphotographs of H&E-stained histological sections of some of these 
representative ErbB2-induced mammary tumours. 
 
              
Figure 6.1. Average number of mammary tumours induced by activated ErbB2 
transgene in the experimental female mice. The -synuclein KO group recorded a 
slightly, but not significantly, higher number of mammary tumours (P = 0.30 using 
Wilcoxon’s rank sum test). 
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Figure 6.2. Photographs of dissected NK hemizygous, -synuclein KO females 
showing multifocal tumours induced by the activated ErbB2 transgene in the different 
mammary glands. 
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Figure 6.3. Photographs of dissected NK hemizygous, -synuclein Wt females 
showing multifocal tumours induced by the activated ErbB2 transgene in the different 
mammary glands. 
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Figure 6.4. Microphotographs of H&E-stained histological sections of representative 
ErbB2-induced mammary tumours. Right two panels: -synuclein Wt mammary gland 
showing multifocal tumour with epithelia-derived tumour cells and little adjacent 
normal tissue; Scale bars = 500 µm for upper panel and 200 µm for lower inset 
panel. Left upper panel: -synuclein KO mammary gland showing multifocal tumour 
with epithelia-derived tumour cells and adjacent normal tissue; Scale bar = 500 µm. 
Left lower panel: -synuclein KO epithelia-derived tumour cells with no normal 
mammary tissue; Scale bar = 200 µm. 
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As transcription of the NK transgene is driven by an MMTV promoter that responds 
to elevated levels of progesterone during pregnancy, and to avoid any possible 
confounding effect of age on the levels of circulating progesterone and on the 
induction of mammary tumours by activated ErbB2, age at parity in the -synuclein 
Wt and -synuclein KO experimental females was compared. As can be seen in 
figure 6.5 below, the average age at parity was almost equal, being 79 days in the -
synuclein Wt and 78 days in the -synuclein KO experimental females. Non-
parametric statistical analysis was still carried out to confirm that there was no 
significant difference between the two genotypes (P = 0.94 using Wilcoxon’s rank 
sum test). 
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Figure 6.5. Age at parity in the -synuclein Wt and -synuclein KO experimental 
female mice. Upper panel: average age at parity in the -synuclein Wt and -
synuclein KO experimental female mice. Lower panel: non-parametric “survival” plot 
with the Kaplan-Meier method for age at parity in the -synuclein Wt and -synuclein 
KO experimental females. No significant difference in age at parity between the two 
genotypes was found (P = 0.94 using Wilcoxon’s rank sum test). 
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6.2.2. -synuclein KO mammary glands exhibited accelerated onset of tumours 
induced by activated ErbB2 transgene 
As tumour incidence was 100% in both -synuclein Wt and KO experimental 
females, concluding that -synuclein is not essential for the induction of mammary 
tumours by activated ErbB2, the timing of tumour onset was next investigated. 
Mammary tumours were detected by palpation starting at an age of 116 days in the 
-synuclein KO experimental females and at an age of 131 days in the -synuclein 
Wt females. Considering the age at which the first palpable tumour was detected in 
each experimental animal, no statistically significant difference was seen between -
synuclein KO and -synuclein Wt experimental groups (P = 0.20 using Wilcoxon’s 
rank sum test). The median age (at which 50% of the first palpable tumours were 
already detected) was 149 and 151 days, and the mean age was 147 and 155 days, 
respectively. However, as can be seen in figure 6.6 the Kaplan-Meier curves show a 
trend for the first palpable tumours in the -synuclein KO females to be detected at 
an earlier age compared to the first palpable tumours in the -synuclein Wt females. 
When all palpable tumours (including the first palpable ones) in all animals in each 
group were taken into account, the median age at which tumours were detected was 
significantly lower in the -synuclein KO animals (P = 0.01 using Wilcoxon’s rank 
sum test; N = 132 and 118, respectively). Tumour latency (median), defined here as 
the age at which 50% of the formed tumours in the group were detected, was 165 
days in the -synuclein KO females and 179 days in the -synuclein Wt females, and 
the mean age was 172 and 178 days, respectively. This accelerated latency can be 
graphically seen in figure 6.7 where the Kaplan-Meier curves appear separated for 
the most part, especially at the earlier events. 
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Figure 6.6. Age at detection of the first palpable tumour. Upper panel: average age 
at which the first palpable tumours were detected in the -synuclein Wt and -
synuclein KO experimental female mice. Lower panel: non-parametric “survival” plot 
with the Kaplan-Meier method for the incidence of age at detection of first palpable 
tumour in the -synuclein Wt and -synuclein KO experimental females. Although no 
statistically significant difference between the two groups was found (P = 0.20 using 
Wilcoxon’s rank sum test), the first palpable tumours in the KO group tended to 
occur earlier as seen by the red curve. 
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Figure 6.7. Age at detection of all palpable tumours. Upper panel: average age at 
which palpable tumours were detected in the -synuclein Wt and -synuclein KO 
experimental female mice. Lower panel: non-parametric “survival” plot with the 
Kaplan-Meier method for age at tumour detection in the -synuclein Wt and -
synuclein KO experimental females. A highly significant difference in tumour latency 
was found between the two genotypes (P=0.01 using Wilcoxon’s rank sum test), with 
the KO tumours being detected significantly earlier than the Wt ones. 
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This interesting result of -synuclein gene deletion accelerating the timing of tumour 
onset was not actually anticipated. This was in light of the available reports on the 
positive effect of -synuclein overexpression on stimulation of cancer cell growth, 
proliferation, survival, motility and metastasis, which inclined us to expect deletion of 
the gene to retard the development and progression of mammary tumours. 
Therefore, the previously highlighted positive correlation between ErbB2 and -
synuclein expression, observed in both human and mouse mammary tumour tissue 
and cell lines, might suggest a possible involvement of -synuclein in some sort of 
negative regulation of the process of ErbB2-induced mammary gland 
tumourigenesis. A similar effect was reported in a study by Zhou and colleagues in 
which -synuclein expression was reported to be downregulated in approximately 
60% (16/27) of human esophageal squamous cell carcinoma (ESCC) samples while 
it was upregulated in only 22% (6/27) of the samples and was not changed in 5 
samples (Zhou et al., 2003). They further ectopically overexpressed -synuclein in 
ESCC 9706 cell line and found it to retard the growth rate in either low or high serum 
medium and to inhibit the transformation ability of the cells growing in soft agar. Their 
findings led to the conclusion that -synuclein may act as a negative regulator in 
human ESCC development. In the current study, knocking out -synuclein may have 
resulted in the lifting of some kind of negative regulation imposed upon the process 
of ErbB2-induced tumourigenesis, leading ultimately to the acceleration of the 
process and the observed earlier onset of mammary tumours. In brief, the definite 
genetic effect of -synuclein gene deletion on an FVB genetic background was the 
acceleration of the timing onset of mammary tumours induced by the activated 
ErbB2 receptor tyrosine kinase in the mammary epithelium. 
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6.2.3. Deletion of -synuclein gene had no significant effect on the growth of 
ErbB2-induced mammary tumours 
As seen above, deletion of -synuclein gene did not prevent the formation of 
mammary tumours by activated ErbB2 transgene but rather unexpectedly 
accelerated the timing of tumour onset. To investigate whether deletion of -
synuclein gene affected tumour growth, the age at which tumours reached a size of 
250 mm3 was considered. Many tumours included in the above investigations were 
not included in this analysis as they were smaller than 250 mm3 at the time the 
animal had to be sacrificed. Figure 6.8 below shows that ErbB2-induced tumours in 
the -synuclein KO experimental females reached this tumour size when females 
were on average 192 days of age, compared to an average age of 201 days in the -
synuclein Wt females. This difference was “marginally” significant (at the verge of 
statistical significance) (P = 0.08 using Wilcoxon’s rank sum test; N = 76 and 69, 
respectively). This may have biological significance as the Kaplan-Meier curves 
show clear separation for the most part, pointing to a slightly faster growth of the -
synuclein KO tumours. 
However, as this result may include an effect of an earlier tumour onset in the -
synuclein KO mammary epithelium, assuming tumour induction/formation and 
tumour growth to be two separate processes, the time it took for tumours to grow 
from a size of 250 mm3 to a size of 1500 mm3 was considered. These sizes were 
chosen as they allowed inclusion of the largest size span and tumour numbers 
possible: most formed tumours could not be included in this analysis because 
adjacent tumours fused after reaching a size of 250 mm3 and many other tumours 
contained large blood-filled cysts that did not represent growth of tumour tissue. As a 
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result, only 9 KO and 8 Wt tumours were available for this tumour size growth 
analysis. Figure 6.9 below presents this result graphically. The -synuclein KO and -
synuclein Wt experimental groups did not differ, with almost equal number of days 
(21 and 22, respectively) required for their tumours to grow from a size of 250 mm3 
to a size of 1500 mm3 (P = 0.77 using Wilcoxon’s rank sum test). Thus, deletion of -
synuclein gene seems to have no effect on the growth of formed ErbB2-induced 
mammary tumours, although this result must be treated with caution as it is based on 
a rather small sample size. 
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Figure 6.8. Age at which palpable tumours reached a size of 250 mm3. Upper panel: 
average age at which palpable tumours reached a size of 250 mm3 in the -synuclein 
Wt and -synuclein KO experimental female mice. Lower panel: non-parametric 
“survival” plot with the Kaplan-Meier method for age at reaching a 250 mm3 size in 
the -synuclein Wt and -synuclein KO experimental females: a “marginally” 
significant difference between the two genotypes was observed (P = 0.08 using 
Wilcoxon’s rank sum test; N = 69 and 76, respectively). 
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Figure 6.9. Effect of -synuclein gene deletion on tumour growth. Upper panel: 
average number of days required for palpable tumours induced in the -synuclein Wt 
and -synuclein KO experimental female mice to grow from a size of 250 mm3 to a 
size of 1500 mm3. Lower panel: non-parametric “survival” plot with the Kaplan-Meier 
method for number of days required for tumours from -synuclein Wt and -synuclein 
KO experimental females to grow from a size of 250 mm3 to a size of 1500 mm3: no 
significant difference between the two genotypes was found (P = 0.77 using 
Wilcoxon’s rank sum test; N = 8 and 9, respectively). 
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6.2.4. Metastasis and animal survival are not affected by deletion of -synuclein 
gene in the NK model 
Metastasis is a crucial aspect of cancer progression and is the main cause of death 
in cancer patients. A strong correlation between aberrant expression of -synuclein in 
primary tumours and progression to distant metastases in patients with different 
cancer types was reported (Liu et al., 2005). Further studies, particularly in breast 
cancer (Guo et al., 2007; Wu et al., 2007; Wu et al., 2003), and in liver cancer (Zhao 
et al., 2006), confirmed the late stage-specific aberrant expression of -synuclein in 
tumours and its correlation to metastasis. The positive role of -synuclein 
overexpression in invasion and metastasis of breast cancer cells was shown both in 
vitro and in vivo (Jia et al., 1999). 
In the current study, the effect of -synuclein gene deletion on metastasis in the NK 
mouse model was investigated by visual inspection of body organs upon animal 
sacrifice and by histological investigations of kidney and lung tissues. No signs of 
lumps or tumour tissue were seen in the different organs inspected visually. H&E-
stained histological sections of liver did not reveal any metastasis either. However, 
histological investigations of H&E-stained histological sections of the lungs confirmed 
metastasis to have occurred in both -synuclein KO and -synuclein Wt experimental 
females with approximately equal proportions, 12/21 (57 %) and 13/21 (62 %), 
respectively. Figure 6.10 below shows metastases in H&E-stained histological 
sections of lungs from both genotypes. Thus, deletion of -synuclein gene had no 
effect on metastasis of mammary tumour cells induced by activated ErbB2 in the NK 
mouse model. 
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In this study, survival of the experimental females was conditional upon tumour 
growth to a diameter of 20 mm, as required by the Home Office regulations. The age 
at which the animals had to be sacrificed was then largely dependent on the overall 
processes of tumour development, including timing of tumour onset, growth and 
progression. Figure 6.11 below shows the average age at sacrifice and a survival 
plot for the -synuclein KO and -synuclein Wt experimental females. The -synuclein 
KO experimental females had a slightly younger age at sacrifice than the -synuclein 
Wt experimental ones, averaging 216 and 224 days of age, respectively. However, 
this 8 day-difference was not statistically significant (P = 0.34 using Wilcoxon’s rank 
sum test). In fact, the median age at which 50% of the animals had to be sacrificed 
was almost equal, being 218 and 219 days, respectively. Therefore, deletion of -
synuclein gene had no effect on the overall development and progression of 
mammary gland tumourigenesis induced by the activated ErbB2 transgene on an 
FVB genetic background. 
In conclusion, results of our study presented in this chapter clearly demonstrate that 
endogenous -synuclein is not required for development, growth and metastasis of 
mammary tumours. Moreover, all used endpoints demonstrated a trend for 
accelerated tumourigenesis in the absence of -synuclein. Thus we proved that a 
widely accepted idea about a role of this protein as a trigger and/or promoter of 
tumourigenesis and metastasis is not necessarily true. It is feasible that the 
increased levels of -synuclein observed in advance-stage tumours and metastases 
might reflect activation of pathways that retard rather than promote these processes. 
Further studies are required to clarify the role of -synuclein in these tumours. 
Looking retrospectively on the design of the in vivo experiments, one can conclude 
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that the used model of activated ErbB2-dependent mammary gland tumourigenesis 
was not the optimal choice for this study. Taking into account the potential 
acceleration of tumour development and growth in the absence of -synuclein, it 
would be preferable to employ a less aggressive model, for instance transgenic mice 
of the “N202” line (expressing unmodified ErbB2 receptor) that develop smaller and 
less tumours with significantly later onset and smaller growth rate. This might 
emphasise the effect of -synuclein depletion on at least some of the studied 
endpoints and produce clear evidence that endogenous -synuclein has a negative 
effect on mammary gland tumourigenesis.  
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Figure 6.10. Effect of -synuclein gene deletion on tumour metastasis. Metastases to 
the lungs were observed in both -synuclein KO and -synuclein Wt experimental 
females with approximately equal proportions. Left two panels: arrows indicate 
metastases in -synuclein KO female lungs; scale bars = 500 µm. Right two panels: 
arrows indicate metastases in -synuclein Wt female lungs; scale bar = 500 µm in 
the upper panel and 200 µm in the lower panel. 
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Figure 6.11. Effect of -synuclein gene deletion on survival. Upper panel: average 
age of -synuclein Wt and -synuclein KO experimental female mice at sacrifice (an 
animal was sacrificed when the longer tumour diameter reached 20 mm). Lower 
panel: non-parametric survival plot with the Kaplan-Meier method for age at sacrifice 
in the -synuclein Wt and -synuclein KO experimental females: no significant 
difference was found between the two genotypes (P = 0.34 using Wilcoxon’s rank 
sum test; N = 21 and 22, respectively). 
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Chapter 7. General discussion and conclusions 
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Breast cancer is the most common cancer in women worldwide. In the year 2010, 
approximately 1.5 million people were diagnosed with the disease, amounting to 
nearly 16% of all female cancers. In the same year, the disease killed 11556 women 
and 77 men in the UK alone (CancerResearchUK, 2012). Despite the availability of 
some anti-cancer drugs, only moderate success has been achieved in the overall 
survival rates. This is because most patients undergo recurrence largely due to 
resistance that tumours eventually develop to drugs used for treatment. Success in 
improving the existing treatments and developing more effective ones would 
ultimately come from increased knowledge of the disease, especially at the cellular 
and molecular levels. 
-synuclein has been claimed to play a role in mammary gland tumourigenesis. Its 
overexpression in cancer cells was shown to inhibit apoptosis and stimulate growth, 
proliferation, survival, motility and metastasis. In transgenic mice, aberrant 
expression of -synuclein stimulated ligand-dependent ER- signalling, leading to a 
highly proliferative pregnancy-like phenotype of mammary epithelial cells and 
branching morphology. However, the role of endogenous -synuclein in mammary 
gland tumourigenesis has not been studied in an appropriate in vivo model. 
Previously in our lab, an observation was made correlating the expression of -
synuclein with that of ErbB2 receptor tyrosine kinase in the mouse mammary tumour 
cell line MG1361. This cell line was originally established from a mammary 
adenocarcinoma isolated from the transgenic breast cancer mouse line FVB-
Tg(MMTV-ErbB2)NK1Mul/J (NK model) chosen for this project. The question was 
thus raised whether -synuclein was required for the development and/or 
progression of ErbB2-induced mammary gland tumourigenesis. To this end, -
synuclein knockout mice on C57BL6 genetic background were backcrossed for 
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several generations with FVB mice and finally intercrossed with mice of NK model to 
investigate the effect of -synuclein gene deletion on the development and 
progression of ErbB2-induced mammary tumours. In parallel, the effect of -
synuclein gene deletion on the normal development of mammary gland was 
investigated in both virgin glands as well as 14.5 day gestating mammary glands. 
To further investigate the observed correlation between the expression of -synuclein 
and that of ErbB2, mouse and human mammary tumour cell lines that are known to 
be either positive or negative for the ErbB2 protooncogene were investigated for -
synuclein expression. The results of these investigations supported a previous 
suggestion that -synuclein expression is positively correlated with that of ErbB2 at 
both the mRNA and protein levels. According to molecular weight, -synuclein was 
detected mostly as a monomer, a dimer or both, although trimer forms were seen in 
some cell lines but at much lower levels. Furthermore, aberrant expression of -
synuclein was detected in mammary tumour tissues isolated from both ErbB2-
positive models (N202 and NK) as well as from Blg-Cre+ BRCA2fl/fl p53fl/fl breast 
cancer model, with -synuclein expressed mostly as a presumable dimer. This notion 
of oligomerization was further supported when enzymatic tests for N-linked 
glycosylation and phosphorylation failed to detect any change in electrophoretic 
mobility of -synuclein protein. This suggests that dimerization might be a functional 
aspect of the small, cytoplasmic -synuclein protein. 
As few reports claimed that the protein may localize to various subcellular structures 
including centrosomes, mitotic spindle fibers and midbody, and that it may even 
translocate to the nucleus under stress conditions, the subcellular localization of -
synuclein in the cell line MG1361 was investigated using highly specific, affinity 
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purified antibody previously produced and characterised in our laboratory. This cell 
line was selected because it was originally established from the same NK mouse 
model used for in vivo experiments in the current study. The results showed that -
synuclein had cytoplasmic localization and in line with the majority of previous 
reports, it appeared to co-localize neither with -tubulin at the centrosomal region of 
dividing cells nor with β-actin in the cultured cells. Moreover, it was not seen co-
localized with α-tubulin in the microtubule spindle fibers, nor was it observed 
associated with α-tubulin at the midbody during cytokinesis of dividing cells. The 
different results from the few reports above could be due to different behaviours of -
synuclein in different cell types and/or to different conditions of cell growth, or to non-
specific binding of antibodies used to certain intracellular structures, which is a 
known phenomenon for poorly purified antibodies with low specificity. 
Investigations of -synuclein protein in normal FVB mouse mammary glands did not 
detect any expression in the epithelium lining the mammary ducts, indicating that it is 
not expressed in the normal epithelial cells of the mammary gland. However, the 
protein was detected in endothelial cells of small blood vessels, in autonomic nerve 
fibers innervating the gland and in the narrow cytoplasmic strips of white adipocytes 
making up most of the mammary gland stroma. Deletion of -synuclein gene did not 
have any effect on the normal development of the mammary gland. The extent of 
epithelial ducts’ elongation and branching morphology was not affected during 
puberty, nor was the development and differentiation of lobuloalveoli during 
gestation. The -synuclein KO mammary glands produced normal amounts of milk as 
evidenced by the nursed pups that developed as normal as pups of Wt mothers. 
Thus, gestation/lactation/involution cycle in the -synuclein KO mammary glands 
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proceeded normally. These results indicate that -synuclein is not required for the 
biological processes governing the normal development of the mammary gland at 
any developmental stage - embryonic, pubertal or reproductive. 
Ablation of -synuclein did not prevent induction of mammary gland tumours by 
activated ErbB2 transgene in mammary gland epithelium. Multifocal tumours were 
formed in the majority of the 5 pairs of mammary glands in most experimental female 
mice. The experimental ErbB2 hemizygous, -synuclein KO females developed 
slightly, but not significantly, more tumours than the ErbB2 hemizygous, -synuclein 
Wt littermates, demonstrating that -synuclein is not essential for the induction of 
mammary tumours by activated ErbB2. However, tumour latency was significantly 
shorter in the -synuclein KO animals than in the -synuclein Wt females, being 165 
days and 179 days, respectively (P = 0.01 using Wilcoxon’s test). This accelerated 
tumour onset suggests that the observed correlation between -synuclein and ErbB2 
expression in human and mouse mammary tumour cell lines and tissues might 
underlie a negative regulation imposed by -synuclein on the process of ErbB2-
induced mammary gland tumourigenesis. A similar result was observed by Zhou and 
co-workers in human esophageal squamous cell carcinoma samples where -
synuclein was downregulated, and when ectopically overexpressed in ESCC 9706 
cell line it retarded the growth rate and inhibited the transformation ability of the 
cancer cells. 
Despite accelerating tumour onset, -synuclein gene deletion seems to have no 
significant effect on the growth rate of formed ErbB2-induced mammary tumours as 
both KO and Wt tumours required about the same number of days to advance from a 
size of 250 mm3 to a size of 1500 mm3, 21 and 22 days, respectively, although this 
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result must be treated with caution as it is based on a rather small sample size, N = 9 
and 8, respectively. Similarly, metastasis of mammary tumour cells induced by 
activated ErbB2 in the NK mouse model was not significantly affected by the 
absence of -synuclein. The -synuclein KO experimental females had a slightly, but 
not significantly, younger age at sacrifice than the -synuclein Wt experimental ones, 
averaging 216 and 224 days of age, respectively. 
In conclusion, our results clearly demonstrate that endogenous -synuclein is not 
required for induction, growth and progression of mammary tumours. Rather, all 
used endpoints demonstrated a trend for accelerated tumourigenesis in the absence 
of -synuclein in the NK model. It is feasible that the aberrant expression of -
synuclein reported in advance-stage tumours and metastases reflects activation of 
pathways and mechanisms aimed at repressing rather than enhancing 
tumourigenesis. Hence, the widely accepted idea of -synuclein protein having an 
oncogenic property is not necessarily true, at least regarding ErbB2-induced 
tumourigenesis. Further studies are required to clarify the role of -synuclein in these 
tumours. Considering the observed trend towards accelerating the process of 
tumourigenesis, we recommend utilizing a less aggressive ErbB2 model to better 
reveal any significant effects -synuclein ablation may have on the process. This may 
include the “N202” mouse model (expressing Wt ErbB2 receptor) which induces less 
and smaller tumours with significantly later onset and smaller growth rate. This might 
emphasise the effect of -synuclein depletion on at least some of the studied 
endpoints and produce clear evidence that endogenous -synuclein may negatively 
regulate the process of mammary gland tumourigenesis. 
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Future prospects 
As -synuclein was reported to have a positive effect on proliferation, migration, 
metastasis and survival of breast cancer cells, we anticipated the loss of its function 
to retard development of mammary tumours. Unexpectedly, however, its absence 
led to rather slightly accelerated mammary gland tumourigenesis induced by the 
constitutively active mutant ErbB2. We pursue conducting the same line of 
investigation but utilizing a less aggressive ErbB2 tyrosine kinase form for mammary 
tumour induction, that of the N202 model.  This might emphasise the effect of -
synuclein depletion on tumour growth rate, metastasis and survival, and produce 
clear evidence that endogenous -synuclein may negatively regulate the process of 
mammary gland tumourigenesis. 
The results obtained in this study will be published as two different papers. One 
paper will report the observed null effect of deleting -synuclein gene on the normal 
development of mammary gland. It will highlight the fact that both wild type and 
knockout females underwent similar developmental changes of mammary gland at 
all stages, fetal, pubertal and reproductive. The second paper will report the 
unexpected effect of slight acceleration of ErbB2-induced mammary gland 
tumourigenesis upon deletion of -synuclein gene, revealing the significantly shorter 
tumour latency and slightly shorter survival.      
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Appendix 
 
Appendix 1. Conventional PCR genotyping for selection of the breeders, 
control and experimental animals. 
 
             
 
             
Upper panel: -synuclein genotyping for selection of breeder, control and 
experimental animals. Three primers, with a common upstream primer for both Wt 
and KO alleles and a specific downstream primer for each, produced two amplified 
fragments, a wild-type fragment of 480 bp and a knock-out one of 397 bp. 
Lower panel: a 622 bp fragment amplified from NK transgene for selection of 
experimental females. 
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Appendix 2. qRT-PCR for selection of the NK homozygous male breeder parent 
used for generating the NK hemizygous experimental females. 
 
                     
Real-time PCR utilizing CYBR Green chemistry was used to detect amplification of 
the NK transgene and the housekeeping gene GAPDH (for use as an internal 
control). 243/263, 264/265 and 255/266 represent NK transgene homozygous, NK 
transgene hemizygous and Wt genotypes, respectively. Fold change was calculated 
using the 2-ΔΔCt comparative method. (RQ: relative quantification). 
